

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Study protocol: A mixed-methods investigation of barriers and needs in mental healthcare of adults with autism and recommendations for future care (BarrierfreeASD)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061773
Article Type:	Protocol
Date Submitted by the Author:	04-Feb-2022
Complete List of Authors:	David, Nicole; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Dückert, Sophia; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Gewohn, Petia; University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy König, Hannah; University Medical Center Hamburg-Eppendorf, Department of Health Economics and Health Services Research Rahlf, Pascal; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Erik, Frank; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Vogeley, Kai; University of Cologne, Department of Psychiatry and Psychotherapy Schöttle, Daniel; University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy Konopka, Alexander; University Medical Center Hamburg-Eppendorf, Department of Health Economics and Health Services Research Schulz, Holger; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Peth, Judith; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology
Keywords:	Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Adult psychiatry < PSYCHIATRY, MENTAL HEALTH

SCHOLARONE™
Manuscripts

1
2
3
4 **Study protocol: A mixed-methods investigation of barriers and needs in mental healthcare of adults**
5 **with autism and recommendations for future care (BarrierfreeASD)**
6
7
8
9

10
11
12
13 Nicole David^{1,*}, Sophia Dücker¹, Petia Gewohn², Hannah König³, Pascal Rahlff¹, Frank Erik¹, Kai
14 Vogeley⁴, Daniel Schöttle², Alexander Konnopka³, Holger Schulz¹, & Judith Peth¹
15
16
17

18
19
20 ¹Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg,
21 Germany; ²Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-
22 Eppendorf, Hamburg, Germany; ³Department of Health Economics and Health Services Research,
23 University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁴Department of Psychiatry,
24 Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
25
26
27
28
29
30
31

32
33
34 *Corresponding author: Nicole David, Department of Medical Psychology, Martinistr. 52, 20251
35 University Medical Center Hamburg-Eppendorf, Germany, n.david@uke.de, +49 40 7410 58395.
36
37
38
39
40
41
42

43 **Word count: 3753**
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Autism refers to an early-onset neurodevelopmental condition with characteristic impairments and difficulties in practical living skills, which persist across the lifespan such that autistic adults often require substantial support and comprehensive care. Yet adult healthcare services are frequently unavailable for autistic adults despite considerable individual, familial and socioeconomic burdens. This study seeks to (i) assess current healthcare needs, barriers and burdens related to the lack of services for autistic adults, (ii) develop specific recommendations for a need-oriented model of care, and (iii) evaluate its future implementation.

Methods and analysis

A mixed-methods design with three phases will be conducted. In *Phase 1*, current mental healthcare of autistic adults will be assessed at three levels (individual, structural and professional) and from three perspectives (autistic adults, relatives and healthcare providers) using (i) focus groups/ interviews (qualitative data) and (ii) large-scale online surveys (quantitative data). Furthermore, service utilization patterns and related costs will be estimated. In *Phase 2*, recommendations for a future model of care for autistic adults will be derived based on Phase 1, considering the heterogeneous and complex needs within the autism spectrum and specifying indications for recommended services. In *Phase 3*, these will again be evaluated by the three stakeholder groups using mixed-methods and analyzed regarding feasibility of implementation and cost-effectiveness. Our study will, thus, contribute to a better translation of recommendations into practice to reduce disability, burden and costs related to ineffective healthcare and improve outcomes for autistic adults and those who support them.

Ethics and dissemination

This study was approved by the Local Psychological Ethics Commission of the Center for Psychosocial Medicine at the University Medical Center Hamburg-Eppendorf (LPEK-0227). Findings will be

1
2
3
4 disseminated via scientific meetings and peer-reviewed journals. Cooperating partners and associations
5
6 will be informed about the study's course and findings by regular newsletters and meetings.
7
8
9

10 11 **Registration**

12
13 This study protocol was pre-registered at the Open Science Framework (OSF; osf.io/5x8pg).
14
15

16 17 18 **Keywords**

19
20 Autism spectrum disorder (ASD); autistic adults; transition; relatives; focus groups; mixed-methods;
21
22 healthcare; health economics; participatory research; implementation research
23
24
25
26
27
28

29 30 **ARTICLE SUMMARY**

31 32 **Strengths and limitations of this study**

- 33
34 • Systematic analysis of current mental healthcare for autistic adults in Germany addressing the
35 perspectives and needs of autists, relatives and healthcare providers. Mixed-methods and health
36 economic analyses to ensure a comprehensive picture and understanding of all perspectives.
37
38
- 39 • Threefold, systematic approach: (1) healthcare and needs analysis, (2) subsequent development of
40 specific recommendations for all relevant stakeholders and of a need-oriented, personalized future
41 model of care for autistic adults, (3) evaluation and analysis of future implementation
42
43
- 44 • Participatory research approach by (1) assessing the perspectives of those who are affected, (2) getting
45 input and feedback from relevant stakeholders throughout all project phases, (3) engaging researchers
46 with autism and clinical researchers, who also work in mental healthcare of autistic adults.
47
48
- 49 • No direct implementation of the developed model within the course of the study. Future funding will
50 be necessary to test implementation, clinical effectiveness and sustainability, for example, within a
51 randomized controlled trial.
52
53
54
55
56
57
58
59
60

INTRODUCTION

Autism spectrum disorder (ASD) or, simply, autism refers to an early-onset lifelong neurodevelopmental condition, which occurs at an estimated prevalence rate of about 1% up to 2%^{1 2}. Autism is characterized by impairments in social interaction and communication as well as restrictive and repetitive behaviors, including abnormalities in sensory information processing and difficulties in practical living skills³. These impairments persist across adulthood such that adults with autism often require external, substantial support and comprehensive care across the lifespan. Yet, autism as a traditionally conceived childhood disorder is commonly underrepresented (i.e., not diagnosed or treated) in healthcare services for adults despite considerable healthcare needs of autistic adults, as shown by increased rates of comorbid medical conditions, premature mortality or risk of suicide⁴⁻⁸. In addition, deficits in effective and cost-efficient healthcare utilization have been reported for autistic adults, indicated by limited use of general preventive healthcare services such as vaccinations or checkups⁷, higher outpatient and emergency room visits, and increased drug prescription claims and use^{8 9}. Non-utilization correlates positively with co-morbidity rates, which correlate positively with chronification, long-term psychosocial impairment, healthcare expenditures and negatively with health-related quality of life in autistic adults^{8 10-12}. In addition to this international evidence, a recent study also analyzed autism-related healthcare service use and attributable costs in Germany, and showed similar results and costs comparable to those of patients suffering from schizophrenia¹³. This highlights the complexity of needs associated with autism in adulthood and the pervasive need of a more efficient, extended healthcare system meeting those needs¹⁴. The latter notion is also reflected in the emergence of “autism strategies” all over Europe, which emphasize the development of extended healthcare structures.

Multiple difficulties and barriers prevent effective and efficient healthcare for adults with autism¹⁵⁻¹⁸. Barriers to healthcare have been discussed at different levels, nationally¹⁶ as well as internationally¹⁷⁻²⁴: at (i) an *individual* level due to autism-related social-communicative impairments, perceptual peculiarities or difficulties with practical skills of daily living (e.g., when making appointments), (ii) a *system-related*

1
2
3
4 *or structural* level (e.g., lack of services or reduced service accessibility across healthcare sectors for
5 autistic adults), and (iii) *professional* level (e.g., lack of training/ knowledge of healthcare providers such
6 as general practitioners, diagnosticians and therapists about adult autism). Yet, factors that facilitate
7 healthcare for adults with autism have also been suggested^{17 25 26}. For example, at individual and
8 professional levels, these include appointment coordination via e-mail, special stimulus-reduced waiting
9 areas, autism-specific training for healthcare providers, shared decision making, cooperation with
10 relatives/ partners or more individualized interventions. At the structural level, case managers,
11 coordination through general practitioners, transition management, medical care centers or financial
12 facilitations for healthcare services have been suggested.

13
14
15
16
17
18
19
20
21
22
23
24
25 Among the afore-mentioned barriers and facilitators, assistance to transition from a familiar and
26 guided pediatric care system to a complex and self-managed care system for adults seems particularly
27 important for autism as a neurodevelopmental condition with limited flexibility, rigidity and other
28 stereotypical behavior²⁷⁻²⁹. Assistance with transition could foster self-management of young autistic
29 adults and reduce potential burden of care for relatives. In fact, relatives typically compensate for the lack
30 of assistance or services, thereby often facing extensive personal and financial burden^{30 31} and reduced
31 health-related quality of life³²⁻³⁴. The amount of evidence on the consequences of an insufficient
32 healthcare system for relatives of autistic adults—not only children—is limited. In addition, support from
33 relatives might not always be available considering the increased age of autistic adults, difficult familial
34 relations or high family concordance rates³⁵. With increasing prevalence rates of autism³⁶, however, a
35 rising number of autistic individuals will be transitioning to adult healthcare and needing assistance to
36 access the appropriate healthcare services. Interventions at several levels and assistance with respect to
37 navigation within the healthcare system will also be required to reduce caregiver burden in autism^{30 37}.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55 Increased healthcare demands are also reflected in the recently growing number of German outpatient
56 clinics and other services specifically tailored to adults with autism. These developments certainly
57 represent major advancements. However, adults seeking autism diagnostics in Germany are often

1
2
3
4 confronted with waiting times up to two years for diagnostic appointments and limited access to follow-
5
6 up treatment despite increased demands for mental support³⁸⁻⁴⁰, less desirable health outcomes and
7
8 reduced quality of life⁴¹. Lipinski and colleagues³⁸ showed that autistic adults seeking psychotherapy
9
10 reported that the main reason for not receiving any or insufficient treatment was an expressed lack of
11
12 expertise with respect to autism. In fact, therapists do report challenges and frustrations due to limited
13
14 training on autism despite high motivation for comprehensive care⁴². While there is evidence from
15
16 therapists serving children with autism, there is hardly any evidence on the perspective and needs of adult
17
18 mental healthcare service providers with respect to autism diagnosis and treatment, which indeed require
19
20 specialized training and expertise¹⁴.
21
22
23
24

25 In sum, autistic adults, their relatives as well as healthcare providers face barriers and are in need of
26
27 extended services. Recognizing autism as a lifelong condition will be a fundamental first step. Yet, in
28
29 order to increase access, capacity and quality of care for autistic adults, it will be necessary to (i)
30
31 systematically understand the factors that lead to poorer health status and ineffective healthcare this
32
33 should include perspectives of all people involved in healthcare access for autistic adults;¹⁵, (ii)
34
35 operationalize individual levels of support and define indications for specific services, (iii) to make these
36
37 information easily accessible to all relevant stakeholders, and (iv), finally, implement evidence-based
38
39 healthcare programs based on specific recommendations at professional and structural levels. Previous
40
41 evidence was helpful in identifying barriers and pointing to future directions. Many suggestions, however,
42
43 have yet to find their way into healthcare politics and services, much less being implemented in routine
44
45 practice. In addition, recommendations often lacked specifics or operationalizations with respect to the
46
47 selection of services or interventions depending on the individual level of disability and required support
48
49 (compare to the recent Lancet commission on the future of care in autism: “Crucial factors include
50
51 understanding what works for whom and when, and what are some of the predictable needs and variations
52
53 that need to be considered to support autistic individuals”⁴³).
54
55
56
57
58
59
60

1
2
3
4 Thus, with the current study we seek to, first, systematically analyze current barriers, facilitators and
5
6 unmet needs—including their economic and personal consequences—in mental healthcare of adults with
7
8 autism in Germany at three relevant levels (individual, structural and professional) and from three relevant
9
10 perspectives (autistic adults, relatives and healthcare providers). Second, we seek to use these data to
11
12 develop specific recommendations for a need-oriented, future model of healthcare for autistic adults, also
13
14 considering the heterogeneity within the autism spectrum and individual indications for assisting services.
15
16 Third, this model will be evaluated by the three stakeholder groups and analyzed with respect to
17
18 implementation in healthcare routines and cost-effectiveness. During all phases, the study will strengthen
19
20 a participatory research approach by engaging autism-trained clinicians and autistic adults in the scientific
21
22 process and by collaborating with autism-, parental- and service-related associations. The long-term aim
23
24 of the study is to contribute to more effective healthcare for autistic adults by providing specific
25
26 recommendations for clinical practice and healthcare policies, also improving outcomes for autistic adults
27
28 and those who support them.
29
30
31
32
33
34
35
36
37
38

39 **METHODS AND ANALYSIS**

40
41 This study protocol was written in adherence with the SPIRIT (Standardized Protocol Items for
42
43 Randomized Trials) checklist for study protocols for items applicable to the present protocol of a non-
44
45 interventional, observational study.
46
47
48
49

50 **Study population**

51
52 Three stakeholder perspectives will be assessed: (i) autistic adults with varying degrees of support, (ii)
53
54 close relatives (first or second degree) or partners of autistic adults, (iii) healthcare service providers from
55
56 all relevant professional backgrounds (e.g., primary care, pediatrics, adult and child psychiatry or
57
58 psychotherapy, other medical directions, occupational therapy, speech therapy, physical therapy, social
59
60

1
2
3
4 work, medical care etc.). Participants with autism must be adults (18+ yrs.) and must have a secured
5
6 diagnosis of autism without intellectual disability ($IQ > 70$), sufficient ability to provide informed consent
7
8 and sufficient language skills to answer the questions. Participants with intellectual disability ($IQ < 70$),
9
10 insufficient German skills and ability to give informed consent will be excluded. Participants will be
11
12 recruited throughout Germany using purposive, quota and snowball sampling via the study's
13
14 collaborating network of cooperating partners, publicly available contacts from autism-related
15
16 associations (incl. self-care and caregiver groups), healthcare associations (medical chambers, therapist
17
18 associations, etc.), local and countrywide outpatient clinics as well as social media. Participants will be
19
20 informed in detail about the study and data protection in accordance with the General Data Protection
21
22 Regulation, and informed consent will be obtained prior to participation. No expense allowance will be
23
24 paid (with the exception of possible travel expenses for participation in interviews/focus groups).
25
26
27
28
29
30
31

32 **Study design and data collection**

33
34 The study will evolve over a period of three years (Oct. 2020 - Sept.2023). A three-phase design will be
35
36 implemented (Fig. 1).
37
38
39
40

41 ----- *please insert Figure 1 about here* -----
42
43
44

45 Phase 1: Healthcare and needs analysis

46
47 First, a systematic literature search of national and international evidence on mental healthcare in adults
48
49 with autism will be conducted to identify previously published barriers, facilitators and needs. Results
50
51 will be used to develop guideline questions for qualitative data collection. Second, these guideline
52
53 questions will be administered by trained researchers in semi-structured one-on-one interviews with
54
55 autistic adults (n=15) and structured focus groups with relatives/ partners of autistic adults (n=15) as well
56
57 as healthcare providers (n=15). Based on these qualitative data, current healthcare barriers and facilitators
58
59
60

1
2
3
4 for autistic adults will be assessed. All interviews and focus groups will be audio-recorded. An external,
5 specifically transcription-qualified person will transcribe recordings verbatim. Because of the dynamics
6 of the Covid-19 pandemic, interviews and focus-groups will be conducted online enabled by an online
7 video communication provider. To meet individual difficulties in communication and flexibility,
8 participants with autism will also be given the chance to answer interview questions in a written format,
9 via chat or phone. Third, online surveys will be developed for each stakeholder group. Healthcare relevant
10 close-ended and open-ended items will be generated through consented discussion in the research team
11 based on the themes that emerged from interviews/ focus groups. Separate online surveys will be
12 developed for each stakeholder group (autistic adults; relatives of autistic adults; healthcare providers)
13 that will be used to collect quantitative data in larger samples and provide an overview of the situation in
14 Germany. This mixed-methods approach aims to obtain a complete set of information to develop specific
15 recommendations for a future healthcare model for autistic adults. In order to assess relevant outcomes,
16 patient-related parameters, individual indications for healthcare service delivery and gather enough
17 information for care model development, online surveys will be complemented by standardized,
18 psychometric questionnaires and patient-reported outcomes. More specifically, autists and relatives will
19 also be asked to complete questionnaires related to health-related quality of life (e.g., EQ-5D-5L)⁴⁴,
20 disability/ functioning (e.g., WHODAS 2.0)⁴⁵ and a German version of the “barriers to healthcare”
21 questionnaire²¹. Relatives will additionally be asked to rate their burden of care (e.g., iVICQ/CarerQoL)⁴⁶.
22 Furthermore, from both groups, variables related to disease/healthcare history, utilization of medical and
23 non-medical services, and productivity losses will be collected (e.g., days spent on sick leave, hospital
24 days, physician contacts, or informal care)^{47 48}. Online surveys will be delivered countrywide by an online
25 survey software in German and separate versions provided to autistic adults (n=250), relatives (n=125)
26 and healthcare providers (n=125).

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Phase 2: Development of recommendations for a future healthcare model for autistic adults

1
2
3
4 A systematic literature search on healthcare, treatment or implementation models for autism and related
5 conditions will be conducted and –together with the results from the mixed-methods data in Phase 1—
6
7 fed into developing recommendations for a future healthcare model for autistic adults. The model will
8
9 include recommendations for actions/interventions at different levels (individual, structural and
10
11 professional) and will be addressed to the stakeholder groups (autistic adults; relatives of autistic adults;
12
13 healthcare providers and policy makers/ politics; Figure 2). Given the heterogeneity of symptom severity,
14
15 functional impairments, rates of comorbidity and needed support within the autism spectrum, a multi-
16
17 professional stepped or collaborative care approach as proposed for, e.g., psychosis or depression;⁴⁹
18
19 represents a promising framework for an alternative care model as opposed to current standard care for
20
21 autistic adults (as also suggested by⁴³). Stepped care for autism may range from low-level, evidence-based
22
23 services (e.g., educational programs or information/ consulting about autism and available treatment
24
25 options, e-mental health) over mid-level services (e.g., improved diagnostics, autism-informed
26
27 psychotherapy, occupational or sociotherapy) to high-level services, which are often unavailable to adults
28
29 with autism in Germany (e.g., case managers, integrated care, medical healthcare centers, inpatient care).
30
31 Recommendations for possible individual steps, services offered within each step and indications for
32
33 services will be specified (e.g., symptom severity or level of support according to DSM-5, health status
34
35 or comorbidity rates, psychosocial functioning). Besides recommendations for the specific treatment of
36
37 autistic adults, the future healthcare model will also provide recommendations for relatives of autistic
38
39 adults, healthcare providers and healthcare policy makers/ politics (Fig. 2). For example, relatives or
40
41 partners who support an autistic adult are often in need of support themselves. Thus, the model will also
42
43 include recommendations for relatives. Conversely, for healthcare providers, recommendations could
44
45 include suggestions to advance knowledge about specific needs of autistic adults and promote awareness
46
47 for these needs in different mental healthcare sections. For policy makers like health insurances and
48
49 politicians, recommendations will focus on extended services to reduce structural barriers. These will be
50
51 underlined by the health-economic data collected within Phase 1 and 3.
52
53
54
55
56
57
58
59
60

----- please insert Figure 2 about here -----

Phase 3: Evaluation and implementation analysis

Methods will be analogous to Phase 1 (mixed-methods, qualitative interviews/ focus groups and quantitative online surveys with autistic adults, relatives of autistic adults and healthcare providers) with emphasis on evaluation and implementation of the developed recommendations for a future healthcare model. Based on the "Consolidated Framework for Implementation Research," an implementation of the model will be explored to improve the feasibility of a potential implementation⁵⁰. The developed model and its components will be evaluated by all stakeholder groups in a structured evaluation process based on different dimensions such as acceptability, appropriateness, cost, feasibility and sustainability⁵¹. In addition to the three stakeholder groups, we will invite participants from healthcare politics and policies. Furthermore, participants will be, for example, asked to rate to what extent (i) barriers and needs identified during Phase 1 will be addressed by the model, (ii) suggested services are already implemented in standard German healthcare, (iii) which services might be easier to implement as opposed to others and (iv) give feedback about service requirements (e.g., training, time/ financial resources, personnel). The mixed-methods design (incl. open-ended questions during online surveys) will allow direct feedback and potential indications for modifications. In addition, standardized implementation-related questionnaires will be employed (e.g., ⁵²). As the model's actual implementation is not part of the study, we would like to use this phase to gather enough information, including positive and critical aspects, for a potential implementation. Finally, based on the results of Phase 3 the developed recommendations for improving healthcare for autistic adults will be reviewed and, if necessary, revised.

Sample sizes

1
2
3
4 Based on power calculation, a total of N=1000 participants will be aimed at for the quantitative online
5 surveys. Sample sizes were chosen to allow for (sub)group comparisons with at least medium effect sizes
6 (d=0.50) at a power of 80% and an alpha error of 5%. To compensate for dropouts, participants will be
7 slightly over-recruited. Qualitative data will not be used for direct hypotheses testing so that sample size
8 does not need to be based on power analyses. Here sample size (a total of N=90) was chosen based on
9 previously published recommendations⁵³.

20 **Data analyses**

21
22 *Qualitative data* from Phase 1 and 3 will be analyzed according to the thematic analysis approach⁵⁴ using
23 the software MAXQDA. Deductive or theoretical categories based on previously published evidence
24 relevant to each phase will drive the analyses. Because the study will focus on subjective experiences/
25 perspectives, data analyses will be complemented by an inductive approach. Data analyses will be
26 conducted by two trained researchers. Emerging themes, subthemes and codes will be discussed by the
27 two researchers and agreed upon by the research team. A third researcher will be consulted upon
28 disagreement.

29
30 *Quantitative data* from online surveys in Phase 1 and 3 will be analyzed using the statistical
31 software SPSS and R. For example, we will run descriptive statistics on sample and healthcare-related
32 variables (e.g., waiting times until confirmed diagnosis or treatment). We will analyze frequencies for
33 categorical data and perform statistical group comparisons between subsamples. To determine potential
34 healthcare-related predictors, multiple regression analyses will be applied. Quantitative data will be tested
35 statistically based on 95% confidence intervals.

36
37 *Health-economic analyses* in Phase 1 and 3 will be informed by a previously conducted systematic
38 review of the literature on cost-of-illness and cost-effectiveness studies in autism. In Phase 1, service
39 utilization and productivity losses in the last six months, as well as out-of-pocket payments will be
40 assessed directly for autistic adults. In addition, relatives will also be asked about aspects that might be

1
2
3
4 related to their autistic relative, like informal care provision or reduced working time. To estimate direct
5 costs, service utilization will be evaluated in monetary terms using standardized unit costs^{55 56}. Indirect
6 costs due to productivity losses (e.g. due to incapacity to work) will be estimated with the human capital
7 approach. The estimated costs for autistic adults and relatives will then be compared with the general
8 German population⁵⁷. Based on the skewed distribution of cost data, cost differences will be calculated
9 using generalized linear models with gamma distribution and log-link function. In Phase 3, health-
10 economic analyses will focus on the evaluation of the potential costs and effects of the developed future
11 healthcare model using health-economic modelling. The cost-effectiveness analysis will assess the
12 incremental cost-effectiveness ratio of the developed healthcare model compared to the status quo. This
13 is calculated as the ratio of the difference in costs (between healthcare intervention and status quo) to the
14 difference in health effects of both respective groups. The costs are to be determined from a societal
15 perspective, i.e. in addition to purely medical costs, non-medical costs and monetarily assessed
16 productivity losses will also be taken into account. As a measure of the health effects, i.e. health-related
17 quality of life, quality-adjusted life years (QALYs) will be estimated based on the findings from the EQ-
18 5D-5L⁴⁴.

41 **Patient and public involvement**

42
43 The stakeholders' perspectives are systematically included given the mixed-methods design. Research
44 will be undertaken in close collaboration with federal and local patient, parental and healthcare or autism-
45 related organizations, from which we obtained collaboration agreements prior to submission to the
46 funding agency as well as during the initial course of the study. They will be continuously informed over
47 the course of the study via regular newsletters and meetings and asked to provide feedback during each
48 study phase. During Phase 1 and 3, for example, representatives will also be invited to participate in focus
49 groups and qualitative interviews and asked to support further recruitment of study participants.

1
2
3
4 Information about the project and interim findings will also be made publicly available on a project
5
6 website.
7
8
9
10

11 12 13 **ETHICS AND DISSEMINATION**

14 15 16 **Ethics approval and consent to participate**

17
18 The study will be carried out in accordance with the WMA Declaration of Helsinki and has been approved
19
20 by the Local Psychological Ethics Commission of the Center for Psychosocial Medicine of the University
21
22 Medical Center Hamburg-Eppendorf (ref.# LPEK-0227). Study participation is voluntary and no
23
24 foreseeable risks for participants result from the participation. Participants will be fully informed about
25
26 the aims of the study, data collection, handling and storage. Written informed consent will be obtained
27
28 before participation. Preserving principles of data sensitivity, data protection and confidentiality
29
30 requirements will be met.
31
32
33
34
35

36 37 **Dissemination**

38
39 Findings will be disseminated via national and international scientific meetings and peer-reviewed
40
41 journals in the field of autism and healthcare research. Cooperating partners and associations will be
42
43 informed about the study's course and findings by regular newsletters and biannual meetings.
44
45
46
47
48
49

50 51 **DISCUSSION**

52
53 This study protocol outlines several urgent challenges related to mental healthcare for autistic adults in
54
55 Germany. The study will provide a systematic analysis of the current state of healthcare for adults with
56
57 autism, including barriers and requirements experienced by autistic persons themselves, but also their
58
59 relatives and healthcare providers. The results will be used to facilitate a real-world, data-informed and
60

1
2
3
4 evidence-based future model of healthcare for autistic adults, which seeks to overcome current barriers
5
6 by developing specific practice recommendations at individual, structural and professional levels aiding
7
8 all stakeholder groups. The model will provide suggestions for all involved stakeholders including policy
9
10 makers.
11
12

13 14 15 16 **Strengths and limitations**

17
18 One strength of this study is that it aims to define individual characteristics that might be useful to assess
19
20 a person's need of support and provide specific treatment suggestions and indications for services
21
22 ("understanding what works for whom and when"⁴³). Another strength is that this study will analyze the
23
24 developed model conceptions for future care with respect to implementation chances, acceptability,
25
26 feasibility, sustainability, cost-effectiveness and other dimensions and prepare for a future
27
28 implementation of recommendations. As such, the current study goes beyond previously published
29
30 analyses of current healthcare demands and generic suggestions for improvement of care for autistic
31
32 individuals, adults in particular.
33
34
35

36
37 For a long time, research or healthcare politics have overlooked, neglected or ignored autistic
38
39 individuals and their families in information and decision-making processes^{58 59}. Here participatory
40
41 reserach will be realized in a threefold fashion. First, results will be obtained by directly asking those who
42
43 are affected (autistic adults, relatives, and healthcare providers) about real-world experiences and their
44
45 attitude towards the developed research. Second, researchers serving mental healthcare of adults with
46
47 autism, and researchers with autism will conduct the study. Third, the research will be undertaken in close
48
49 collaboration with patient, parental and healthcare organizations, which will be continuously informed
50
51 over the course of the study and asked to provide feedback during each study phase.
52
53
54

55
56 One limitation of the study is that the developed healthcare model for adults with autism will not
57
58 be practically applied during the course of the study. Future funding will be necessary to test
59
60 implementation, clinical effectiveness and sustainability of the developed recommendations and services,

1
2
3
4 for example, within a randomized controlled trial. This will allow for further refinement and specifics to
5
6 foster large-scale implementation. Yet, as the study is funded by the German Federal Joint
7
8 Committee—the highest decision-making body of the joint self-government of practitioners,
9
10 hospitals and health insurance funds—this study will likely have a direct and immediate impact
11
12 on healthcare policies and contribute to improving outcomes in people and families with autism and
13
14 reducing individual, familial and socioeconomic burdens associated with a lack of services for adults with
15
16 autism.
17
18
19
20
21
22
23
24

25 **Acknowledgements**

26
27 We would like to acknowledge the support of our cooperation partners and supporters: the Autism
28
29 Research Cooperation (afk), autSocial e.V., the Federation of Autism in Germany (Autismus Deutschland
30
31 e.V.), the parent association Autismus Hamburg e.V., the Autism Institute of Hamburg, the Autism
32
33 Institute of Lübeck, the Autism Strategy for Bavaria (Prof. M. Witzmann), Practice for Psychotherapy
34
35 Aida Knabe and others.
36
37
38
39
40

41 **Author contributions**

42
43 HS is the main PI for the study; DS, AK, KV, ND and JP are co-PIs. They all conceptualized and designed
44
45 the study. SD, PG, HK, PR and FE are research staff. SD is also a graduate student. ND and JP mainly
46
47 drafted this manuscript. All authors participated, reviewed and edited the manuscript; all authors approved
48
49 the final version of the manuscript.
50
51
52
53
54

55 **Funding**

56
57 This work was supported by the Innovation Fund of the German Federal Joint Committee (Gemeinsamer
58
59 Bundesausschuss, G-BA, study “*BarrierefreiASS*”/ *grant number*: 01VSF19011 awarded to HS (PI)).
60

1
2
3
4 The funding body had no role in the design of the study or in writing the manuscript, nor will they have
5
6 a role in data collection, analyses or interpretation of data.
7
8
9

10 11 **Competing interests**

12
13 DS received honoraria for lectures from or has been an advisor to Janssen GmbH, ROVI, Lundbeck
14
15 GmbH, Otsuka Pharma GmbH and Takeda. The remaining authors do not declare other competing
16
17 interests.
18
19

20 21 22 23 24 25 **REFERENCES**

- 26
27 1. Baio J, Wiggins L, Christensen DL, et al. Prevalence of Autism Spectrum Disorder Among Children
28
29 Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United
30
31 States, 2014. *MMWR Surveill Summ* 2018;67(6):1-23. doi: 10.15585/mmwr.ss6706a1 [published
32
33 Online First: 2018/04/28]
34
35
36 2. Lundstrom S, Reichenberg A, Anckarsater H, et al. Autism phenotype versus registered diagnosis in
37
38 Swedish children: prevalence trends over 10 years in general population samples. *BMJ*
39
40 2015;350:h1961. doi: 10.1136/bmj.h1961 [published Online First: 2015/04/30]
41
42
43 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.
44
45 Washington, DC2013.
46
47
48 4. Hirvikoski T, Mittendorfer-Rutz E, Boman M, et al. Premature mortality in autism spectrum disorder.
49
50 *Br J Psychiatry* 2016;208(3):232-8. doi: 10.1192/bjp.bp.114.160192 [published Online First:
51
52 2015/11/07]
53
54
55 5. Croen LA, Zerbo O, Qian Y, et al. The health status of adults on the autism spectrum. *Autism*
56
57 2015;19(7):814-23. doi: 10.1177/1362361315577517 [published Online First: 2015/04/26]
58
59
60

- 1
2
3
4 6. Kohane IS, McMurry A, Weber G, et al. The co-morbidity burden of children and young adults with
5
6 autism spectrum disorders. *PLoS One* 2012;7(4):e33224. doi: 10.1371/journal.pone.0033224
7
8 [published Online First: 2012/04/19]
9
10
- 11 7. Nicolaidis C, Kripke CC, Raymaker D. Primary care for adults on the autism spectrum. *Med Clin North*
12
13 *Am* 2014;98(5):1169-91. doi: 10.1016/j.mcna.2014.06.011 [published Online First: 2014/08/20]
14
15
- 16 8. Vohra R, Madhavan S, Sambamoorthi U. Comorbidity prevalence, healthcare utilization, and
17
18 expenditures of Medicaid enrolled adults with autism spectrum disorders. *Autism* 2017;21(8):995-
19
20 1009. doi: 10.1177/1362361316665222 [published Online First: 2016/11/23]
21
22
- 23 9. Vohra R, Madhavan S, Sambamoorthi U. Emergency Department Use Among Adults with Autism
24
25 Spectrum Disorders (ASD). *J Autism Dev Disord* 2016;46(4):1441-54. doi: 10.1007/s10803-015-
26
27 2692-2 [published Online First: 2016/01/15]
28
29
- 30 10. Kamp-Becker I, Schröder J, Remschmidt H, et al. Health-related quality of life in adolescents and
31
32 young adults with high functioning autism-spectrum disorder. *Psychosoc Med* 2010;7:Doc03. doi:
33
34 10.3205/psm000065
35
36
- 37 11. Mason D, Mackintosh J, McConachie H, et al. Quality of life for older autistic people: The impact of
38
39 mental health difficulties. *Res Autism Spect Dis* 2019;63:13-22. doi: 10.1016/j.rasd.2019.02.007
40
41
- 42 12. Mason D, McConachie H, Garland D, et al. Predictors of quality of life for autistic adults. *Autism Res*
43
44 2018;11(8):1138-47. doi: 10.1002/aur.1965
45
- 46 13. Hofer J, Hoffmann F, Dorks M, et al. Health Services Use and Costs in Individuals with Autism
47
48 Spectrum Disorder in Germany: Results from a Survey in ASD Outpatient Clinics. *J Autism Dev*
49
50 *Disord* 2021 doi: 10.1007/s10803-021-04955-4 [published Online First: 2021/03/18]
51
52
- 53 14. Kamp-Becker I, Poustka L, Bachmann C, et al. Study protocol of the ASD-Net, the German research
54
55 consortium for the study of Autism Spectrum Disorder across the lifespan: from a better
56
57 etiological understanding, through valid diagnosis, to more effective health care. *BMC Psychiatry*
58
59 2017;17(1):206. doi: 10.1186/s12888-017-1362-7 [published Online First: 2017/06/05]
60

- 1
2
3
4 15. Calleja S, Islam FMA, Kingsley J, et al. Healthcare access for autistic adults A systematic review.
5
6 *Medicine* 2020;99(29) doi: Artn 20899
7
8
9 10.1097/Md.00000000000020899
10
11 16. Dern S, Sappok T. Barriers to healthcare for people on the autism spectrum. *Adv Autism* 2016;2(1):2-
12
13 11. doi: 10.1108/Aia-10-2015-0020
14
15 17. Mason D, Ingham B, Urbanowicz A, et al. A Systematic Review of What Barriers and Facilitators
16
17 Prevent and Enable Physical Healthcare Services Access for Autistic Adults. *J Autism Dev Disord*
18
19 2019;49(8):3387-400. doi: 10.1007/s10803-019-04049-2 [published Online First: 2019/05/28]
20
21
22 18. Fenikile TS, Ellerbeck K, Filippi MK, et al. Barriers to autism screening in family medicine practice:
23
24 a qualitative study. *Prim Health Care Res* 2015;16(4):356-66. doi: 10.1017/S1463423614000449
25
26
27 19. Malik-Soni N, Shaker A, Luck H, et al. Tackling healthcare access barriers for individuals with autism
28
29 from diagnosis to adulthood. *Pediatr Res* 2021 doi: 10.1038/s41390-021-01465-y
30
31
32 20. Platos M, Pisula E. Service use, unmet needs, and barriers to services among adolescents and young
33
34 adults with autism spectrum disorder in Poland. *Bmc Health Serv Res* 2019;19(1) doi: ARTN 587
35
36 10.1186/s12913-019-4432-3
37
38
39 21. Raymaker DM, McDonald KE, Ashkenazy E, et al. Barriers to healthcare: Instrument development
40
41 and comparison between autistic adults and adults with and without other disabilities. *Autism*
42
43 2017;21(8):972-84. doi: 10.1177/1362361316661261
44
45
46 22. Tint A, Palucka AM, Bradley E, et al. Emergency service experiences of adults with autism spectrum
47
48 disorder without intellectual disability. *Autism* 2019;23(3):792-95. doi:
49
50 10.1177/1362361318760294 [published Online First: 2018/03/02]
51
52
53 23. Nicolaidis C, Raymaker D, McDonald K, et al. Comparison of Healthcare Experiences in Autistic and
54
55 Non-Autistic Adults: A Cross-Sectional Online Survey Facilitated by an Academic-Community
56
57 Partnership. *J Gen Intern Med* 2013;28(6):761-69. doi: 10.1007/s11606-012-2262-7
58
59
60

- 1
2
3
4 24. Nicolaidis C, Raymaker DM, Ashkenazy E, et al. "Respect the way I need to communicate with you":
5
6 Healthcare experiences of adults on the autism spectrum. *Autism* 2015;19(7):824-31. doi:
7
8 10.1177/1362361315576221
9
10
- 11 25. Maddox BB, Crabbe S, Beidas RS, et al. "I wouldn't know where to start": Perspectives from
12
13 clinicians, agency leaders, and autistic adults on improving community mental health services for
14
15 autistic adults. *Autism* 2020;24(4):919-30. doi: 10.1177/1362361319882227 [published Online
16
17 First: 2019/11/02]
18
19
- 20 26. Vogan V, Lake JK, Tint A, et al. Tracking health care service use and the experiences of adults with
21
22 autism spectrum disorder without intellectual disability: A longitudinal study of service rates,
23
24 barriers and satisfaction. *Disabil Health J* 2017;10(2):264-70. doi: 10.1016/j.dhjo.2016.11.002
25
26 [published Online First: 2016/12/03]
27
28
- 29 27. Freitag CM, Poustka L, Kamp-Becker I, et al. Transition in autism spectrum disorders. *Z Kinder Jug-*
30
31 *Psych* 2020;48(6):440-42. doi: 10.1024/1422-4917/a000715
32
33
- 34 28. King C, Merrick H, Le Couteur A. How should we support young people with ASD and mental health
35
36 problems as they navigate the transition to adult life including access to adult healthcare services.
37
38 *Epidemiol Psych Sci* 2020;29 doi: ARTN e90
39
40 10.1017/S2045796019000830
41
42
- 43 29. Enner S, Ahmad S, Morse AM, et al. Autism: considerations for transitions of care into adulthood.
44
45 *Curr Opin Pediatr* 2020;32(3):446-52. doi: 10.1097/Mop.0000000000000882
46
47
- 48 30. Cadman T, Eklund H, Howley D, et al. Caregiver burden as people with autism spectrum disorder
49
50 and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the
51
52 United Kingdom. *J Am Acad Child Adolesc Psychiatry* 2012;51(9):879-88. doi:
53
54 10.1016/j.jaac.2012.06.017 [published Online First: 2012/08/25]
55
56
57
58
59
60

- 1
2
3
4 31. Rogge N, Janssen J. The Economic Costs of Autism Spectrum Disorder: A Literature Review. *Journal*
5 *of Autism and Developmental Disorders* 2019;49(7):2873-900. doi: 10.1007/s10803-019-04014-
6 z
7
8
9
10
11 32. Boehm TL, Carter EW, Taylor JL. Family Quality of Life During the Transition to Adulthood for
12 Individuals With Intellectual Disability and/or Autism Spectrum Disorders. *Am J Intellect Dev*
13 *Disabil* 2015;120(5):395-411. doi: 10.1352/1944-7558-120.5.395 [published Online First:
14 2015/09/01]
15
16
17
18
19
20 33. Johnson N, Frenn M, Feetham S, et al. Autism spectrum disorder: parenting stress, family functioning
21 and health-related quality of life. *Fam Syst Health* 2011;29(3):232-52. doi: 10.1037/a0025341
22 [published Online First: 2011/09/21]
23
24
25
26
27 34. Jones S, Bremer E, Lloyd M. Autism spectrum disorder: family quality of life while waiting for
28 intervention services. *Qual Life Res* 2017;26(2):331-42. doi: 10.1007/s11136-016-1382-7
29 [published Online First: 2016/08/04]
30
31
32
33
34 35. Tick B, Bolton P, Happe F, et al. Heritability of autism spectrum disorders: a meta-analysis of twin
35 studies. *J Child Psychol Psychiatry* 2016;57(5):585-95. doi: 10.1111/jcpp.12499 [published
36 Online First: 2015/12/29]
37
38
39
40
41 36. Matson JL, Kozlowski AM. The increasing prevalence of autism spectrum disorders. *Res Autism Spect*
42 *Dis* 2011;5(1):418-25. doi: 10.1016/j.rasd.2010.06.004
43
44
45
46 37. Iadarola S, Perez-Ramos J, Smith T, et al. Understanding stress in parents of children with autism
47 spectrum disorder: a focus on under-represented families. *Int J Dev Disabil* 2019;65(1):20-30.
48 doi: 10.1080/20473869.2017.1347228
49
50
51
52 38. Lipinski S, Blanke ES, Suenkel U, et al. Outpatient Psychotherapy for Adults with High-Functioning
53 Autism Spectrum Condition: Utilization, Treatment Satisfaction, and Preferred Modifications.
54 *Journal of Autism and Developmental Disorders* 2019;49(3):1154-68. doi: 10.1007/s10803-018-
55 3797-1
56
57
58
59
60

- 1
2
3
4 39. Baldwin S, Costley D. The experiences and needs of female adults with high-functioning autism
5 spectrum disorder. *Autism* 2016;20(4):483-95. doi: 10.1177/1362361315590805 [published
6
7 Online First: 2015/06/27]
8
9
10
11 40. Gawronski A, Kuzmanovic B, Georgescu A, et al. [Expectations concerning psychotherapy of high-
12 functioning adults with autism spectrum disorders]. *Fortschritte der Neurologie-Psychiatrie*
13 2011;79(11):647-54. doi: 10.1055/s-0031-1281734 [published Online First: 2011/10/19]
14
15
16
17 41. Graham Holmes L, Zampella CJ, Clements C, et al. A Lifespan Approach to Patient-Reported
18 Outcomes and Quality of Life for People on the Autism Spectrum. *Autism Res* 2020;13(6):970-
19 87. doi: 10.1002/aur.2275 [published Online First: 2020/03/11]
20
21
22
23
24 42. Brookman-Frazee L, Drahota A, Stadnick N, et al. Therapist Perspectives on Community Mental
25 Health Services for Children with Autism Spectrum Disorders. *Adm Policy Ment Hlth*
26 2012;39(5):365-73. doi: 10.1007/s10488-011-0355-y
27
28
29
30
31 43. Lord C, Charman T, Havdahl A, et al. The *Lancet* Commission on the future of care and
32 clinical research in autism. *The Lancet* 2022;399(10321):271-334. doi: 10.1016/S0140-
33 6736(21)01541-5
34
35
36
37
38 44. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level
39 version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20(10):1727-36. doi: 10.1007/s11136-011-
40 9903-x [published Online First: 2011/04/12]
41
42
43
44
45 45. Ustun TB, Kostanjsek N, Chatterji S, et al. Measuring health and disability : manual for WHO
46 Disability Assessment Schedule (WHODAS 2.0) / edited by T.B. Üstün, N. Kostanjsek, S.
47 Chatterji, J.Rehm. Geneva: World Health Organization, 2010.
48
49
50
51
52 46. Brouwer WB, van Exel NJ, van Gorp B, et al. The CarerQol instrument: a new instrument to measure
53 care-related quality of life of informal caregivers for use in economic evaluations. *Qual Life Res*
54 2006;15(6):1005-21. doi: 10.1007/s11136-005-5994-6 [published Online First: 2006/08/11]
55
56
57
58
59
60

- 1
2
3
4 47. Seidl H, Bowles D, Bock JO, et al. [FIMA--questionnaire for health-related resource use in an elderly
5 population: development and pilot study]. *Gesundheitswesen* 2015;77(1):46-52. doi: 10.1055/s-
6 0034-1372618 [published Online First: 2014/05/09]
7
8
9
10
11 48. Grupp H, Konig HH, Riedel-Heller S, et al. [FIMPsy - Questionnaire for the Assessment of Medical
12 and non Medical Resource Utilisation in Mental Disorders: Development and Application].
13 *Psychiatr Prax* 2018;45(2):87-94. doi: 10.1055/s-0042-118033 [published Online First:
14 2017/01/27]
15
16
17
18
19
20 49. Watzke B, Heddaeus D, Steinmann M, et al. Effectiveness and cost-effectiveness of a guideline-based
21 stepped care model for patients with depression: study protocol of a cluster-randomized controlled
22 trial in routine care. *BMC Psychiatry* 2014;14:230. doi: 10.1186/s12888-014-0230-y [published
23 Online First: 2014/09/04]
24
25
26
27
28
29 50. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research
30 findings into practice: a consolidated framework for advancing implementation science.
31 *Implement Sci* 2009;4:50. doi: 10.1186/1748-5908-4-50 [published Online First: 2009/08/12]
32
33
34
35
36 51. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual
37 distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health*
38 2011;38(2):65-76. doi: 10.1007/s10488-010-0319-7 [published Online First: 2010/10/20]
39
40
41
42
43 52. Lindig A, Hahlweg P, Christalle E, et al. Translation and psychometric evaluation of the German
44 version of the Organisational Readiness for Implementing Change measure (ORIC): a cross-
45 sectional study. *BMJ Open* 2020;10(6):e034380. doi: 10.1136/bmjopen-2019-034380 [published
46 Online First: 2020/06/10]
47
48
49
50
51
52 53. Guest G, Namey E, McKenna K. How Many Focus Groups Are Enough? Building an Evidence Base
53 for Nonprobability Sample Sizes. *Field Methods* 2017;29(1):3-22. doi:
54 10.1177/1525822x16639015
55
56
57
58
59
60

- 1
2
3
4 54. Braun V, Clarke V. What can "thematic analysis" offer health and wellbeing researchers? *Int J Qual*
5
6 *Stud Health Well-being* 2014;9:26152. doi: 10.3402/qhw.v9.26152 [published Online First:
7
8 2014/10/19]
9
10
11 55. Bock JO, Brettschneider C, Seidl H, et al. Ermittlung standardisierter Bewertungssätze aus
12
13 gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation. *Gesundheitswesen*
14
15 2015;77(01):53-61. [published Online First: 15.07.2014]
16
17
18 56. Grupp H, König H-H, Konnopka A. Kostensätze zur monetären Bewertung von
19
20 Versorgungsleistungen bei psychischen Erkrankungen. *Gesundheitswesen* 2017;79(01):48-57.
21
22 [published Online First: 24.09.2015]
23
24
25 57. Grupp H, König HH, Konnopka A. Health care utilisation and costs in the general population in
26
27 Germany. *Health Policy* 2016;120(2):159-69. doi: 10.1016/j.healthpol.2015.11.005 [published
28
29 Online First: 2016/01/23]
30
31
32 58. Pellicano E, Dinsmore A, Charman T. What should autism research focus upon? Community views
33
34 and priorities from the United Kingdom. *Autism* 2014;18(7):756-70. doi:
35
36 10.1177/1362361314529627
37
38
39 59. Pellicano E, Stears M. Bridging Autism, Science and Society: Moving Toward an Ethically Informed
40
41 Approach to Autism Research. *Autism Res* 2011;4(4):271-82. doi: 10.1002/aur.201
42
43
44
45
46
47

48 **FIGURE TITLES**

49 **Figure 1**

50
51
52
53
54
55
56
57
58
59
60
Timeline and three study phases.

55 **Figure 2**

56
57
58
59
60
Future model of mental healthcare for adults with autism: relevant stakeholders and target groups

Phase 1: Healthcare analysis

- Literature search on healthcare of autistic adults
- Mixed-methods:
 - Interviews/ focus groups (*qualitative data*) with autistic adults, relatives & healthcare providers (n=15)
 - Large-scale online surveys (*quantitative data*) in autistic adults (n=250), relatives (n=125) & healthcare providers (n=125)
- Health economic analysis (service utilization and costs)

Phase 3: Evaluation and implementation analysis

- Mixed-methods:
 - Interviews/ focus groups with autistic adults, relatives & healthcare providers (n=15)
 - Large-scale online surveys in autistic adults (n=250), relatives (n=125) & healthcare providers (n=125)
- Health economic analysis (cost-effectiveness)
- Finalisation of best practice recommendations

2021

2022

2023

Phase 2: Model development

Development of specific recommendations for an effective future model of mental healthcare of autistic adults

- data-informed
- evidence-based
- Individualized (stepped-care)

Future healthcare for adults with autism

<i>Autistic adults</i>	<i>Relatives</i>	<i>Healthcare providers</i>	<i>Healthcare politics</i>
<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare for autistic adults • Estimation of individual parameters and operationalized levels of disability and needed support • Specific recommendations for services, treatment options and assistance (e.g., stepped-care) 	<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare for autistic adults and their relatives (e.g., education, counselling, treatment options, assistance) • Specific recommendations for services and assistance to support relatives themselves 	<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare of autistic adults (e.g., education about adult autism, assessment and treatment) • Specific recommendations for services, interventions and assistance • Details on individual indications for the selection of appropriate services 	<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare of autistic adults (e.g., additional healthcare structures/ services such as transition or case management, financial aids)

Recommendations for general services to overcome barriers at individual, professional and structural levels

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 3 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ n/a ___
Protocol version	3	Date and version identifier	___ n/a ___
Funding	4	Sources and types of financial, material, and other support	___ 16/17 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 16 ___
	5b	Name and contact information for the trial sponsor	___ n/a ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 16/17 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ n/a ___

1 Introduction

2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	_____ 4-7 _____
4	rationale			
5				
6		6b	Explanation for choice of comparators	_____ n/a _____
7				
8	Objectives	7	Specific objectives or hypotheses	_____ 6/7 _____
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	_____ n/a _____
11				
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	_____ 7/8 _____
17				
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	_____ 7/8 _____
20				
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	_____ n/a _____
23				
24		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	_____ n/a _____
25				
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	_____ n/a _____
27				
28		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	_____ n/a _____
29				
30	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	_____ n/a _____
31				
32				
33				
34	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_____ (Fig1) _____
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____11_____
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____7(11)_____
5				
6	Methods: Assignment of interventions (for controlled trials)			
7	Allocation:			
8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____n/a_____
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____n/a_____
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____n/a_____
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____n/a_____
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____n/a_____
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____8-11_____
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____n/a_____
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____ n/a _____
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_____ 12/13 _____
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_____ 12/13 _____
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____ n/a _____
11				
12				
13				
14				
15	Methods: Monitoring			
16				
17	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____ n/a _____
18				
19				
20				
21				
22				
23		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____ n/a _____
24				
25				
26	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____ n/a _____
27				
28				
29	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____ n/a _____
30				
31				
32				
33	Ethics and dissemination			
34				
35	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____ 2/3, 13/ _____
36				
37				
38	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____ n/a _____
39				
40				
41				
42				

http://bmjopen-2022-061773 on 23 August 2022. Downloaded from <http://bmjopen.bmj.com/> on June 2, 2023 by guest. Protected by copyright.

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	(8,14)
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	n/a
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	16/17
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	2/3, 13,14
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

Study protocol: A mixed-methods investigation of barriers and needs in mental healthcare of adults with autism and recommendations for future care (BarrierfreeASD)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061773.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Jul-2022
Complete List of Authors:	David, Nicole; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Dückert, Sophia; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Gewohn, Petia; University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy König, Hannah; University Medical Center Hamburg-Eppendorf, Department of Health Economics and Health Services Research Rahlff, Pascal; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Erik, Frank; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Vogeley, Kai; Faculty of Medicine and University Hospital Cologne, Department of Psychiatry and Psychotherapy Schöttle, Daniel; University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy Konnopka, Alexander; University Medical Center Hamburg-Eppendorf, Department of Health Economics and Health Services Research Schulz, Holger; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology Peth, Judith; University Medical Center Hamburg-Eppendorf, Department of Medical Psychology
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Health services research
Keywords:	Health economics < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Adult psychiatry < PSYCHIATRY, MENTAL HEALTH

SCHOLARONE™
Manuscripts

1
2
3
4 **Study protocol: A mixed-methods investigation of barriers and needs in mental healthcare of adults**
5 **with autism and recommendations for future care (BarrierfreeASD)**
6
7
8
9
10
11
12

13 Nicole David^{1,*}, Sophia Dücker¹, Petia Gewohn², Hannah König³, Pascal Rahlff¹, Frank Erik¹, Kai
14 Vogeley⁴, Daniel Schöttle², Alexander Konnopka³, Holger Schulz¹, & Judith Peth¹
15
16
17
18
19

20 ¹Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg,
21 Germany; ²Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-
22 Eppendorf, Hamburg, Germany; ³Department of Health Economics and Health Services Research,
23 University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁴Department of Psychiatry,
24 Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
25
26
27
28
29
30
31
32
33

34 *Corresponding author: Nicole David, Department of Medical Psychology, Martinistr. 52, 20251
35 University Medical Center Hamburg-Eppendorf, Germany, n.david@uke.de, +49 40 7410 58395.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Autism refers to an early-onset neurodevelopmental condition with characteristic impairments and difficulties in practical living skills, which persist across the lifespan such that autistic adults often require substantial support and comprehensive care. Yet, mental health and other services are frequently unavailable for autistic adults despite considerable need for mental healthcare and individual, familial and socioeconomic burdens. This study will (i) examine current needs, barriers and burdens related to ineffective healthcare of autistic adults in Germany, (ii) develop specific recommendations for a need-oriented mental healthcare model, and (iii) evaluate its future implementation.

Methods and analysis

A mixed-methods design with three phases will be conducted. In *Phase 1*, current mental healthcare for autistic adults will be assessed at three levels (individual, structural and professional) and from three perspectives (autistic adults, relatives and healthcare providers) using (i) focus groups/interviews (qualitative data) and (ii) large-scale online surveys (quantitative data). Furthermore, service utilization and related costs will be estimated. In *Phase 2*, recommendations for a future healthcare model will be derived based on Phase 1, considering the heterogeneous and complex needs within the autism spectrum and specifying indications for recommended services. In *Phase 3*, these will again be evaluated by the three stakeholder groups using mixed-methods and analyzed regarding feasibility of implementation and cost-effectiveness. Our study will, thus, contribute to a better translation of recommendations into practice to reduce disability, burden and costs related to ineffective healthcare and improve mental health outcomes for autistic adults and those who support them.

Ethics and dissemination

This study was approved by the Local Psychological Ethics Commission of the Center for Psychosocial Medicine at the University Medical Center Hamburg-Eppendorf (LPEK-0227). Findings will be

1
2
3
4 disseminated via scientific meetings and peer-reviewed journals. Cooperating partners and associations
5
6 will be informed about the study's course and findings by regular newsletters and meetings.
7
8
9

10 11 **Registration**

12
13 This study protocol was pre-registered at the Open Science Framework (OSF; osf.io/5x8pg).
14
15

16 17 18 **Keywords**

19
20 Autism spectrum disorder (ASD); autistic adults; transition; relatives; focus groups; mixed-methods;
21
22 mental healthcare; health economics; participatory research; implementation research
23
24
25
26
27
28

29 30 **ARTICLE SUMMARY**

31 32 **Strengths and limitations of this study**

- 33
34 • Systematic analysis of current mental healthcare for autistic adults in Germany addressing the
35
36 perspectives and needs of autists, relatives and healthcare providers. Mixed-methods and health economic
37
38 analyses to ensure a comprehensive picture and understanding of all perspectives.
39
40
- 41
42 • Threefold, systematic approach: (1) healthcare and needs analysis, (2) subsequent development of
43
44 specific recommendations for all relevant stakeholders and of a need-oriented, personalized future
45
46 model of care for autistic adults, (3) evaluation and analysis of future implementation.
47
- 48
49 • Participatory research approach by (1) assessing the perspectives of those who are affected, (2) getting
50
51 input and feedback from relevant stakeholders throughout all project phases, (3) engaging researchers
52
53 with autism and clinical researchers, who also work in mental healthcare of autistic adults.
54
- 55
56 • No direct implementation of the developed model within the course of the study. Future funding will be
57
58 necessary to test implementation, clinical effectiveness and sustainability, for example, within a
59
60 randomized controlled trial.

INTRODUCTION

Autism spectrum disorder (ASD) or, simply, autism refers to an early-onset lifelong neurodevelopmental condition, which occurs at an estimated prevalence rate of about 1% up to 2%^{1 2}. Autism is characterized by impairments in social interaction and communication as well as restrictive and repetitive behaviors, including abnormalities in sensory information processing and difficulties in practical living skills³. These impairments persist across adulthood such that adults with autism often require external, substantial support and comprehensive care across the lifespan.

Yet, autism as a traditionally conceived childhood disorder is commonly underrepresented (i.e., not diagnosed or treated) in general and mental healthcare services for adults despite considerable healthcare needs of autistic adults, as shown by increased rates of comorbid medical and mental health conditions, premature mortality or risk of suicide⁴⁻⁸. Medically, autism has been associated with increased rates of various conditions including epilepsy, bowel or gastrointestinal disorders, diabetes, etc.^{5 6 8}. In comparison, rates of mental health comorbidity were found to be particularly increased in adults with autism (i.e., more than 80% of patients showed psychiatric comorbidity)⁸, including anxiety disorders and mood disorders but also sleep disturbances, ADHD, even psychosis⁵. These conditions were related to reduced quality of life in autistic adults^{9 10}, suggesting a particular need for mental health services. Despite this need, observations of ineffective or cost-inefficient healthcare utilization have been made for autistic adults with respect to primary or medical healthcare such as preventive services, gynecology, urgent care or emergency department visits^{7 8 11 12} but also to mental health services such as psychiatric, therapeutic, counselling, psychopharmacological or other supporting services¹²⁻¹⁸. Medical and mental health comorbidities in adults with autism were associated with increased barriers to service use¹⁸ as well as healthcare expenditures⁸. Analyses of autism-related mental healthcare expenditures using data from psychiatric outpatient clinics in Germany revealed costs comparable to those attributable to

1
2
3
4 schizophrenia¹⁹. Largest cost components arose from inpatient care, pharmacotherapy and occupational
5 therapy, and costs varied as a function of gender, IQ and diagnosis. Asperger syndrome despite being
6 considered “high-functioning” was associated with higher costs¹⁹ and higher unmet healthcare needs¹⁸.
7 Together this evidence highlights the intensity and complexity of healthcare needs associated with autism
8 in adulthood and the pervasive need of a more efficient, extended healthcare system meeting those
9 needs²⁰, as also emphasized by several national and international “autism strategies” from all over Europe.
10
11
12
13
14
15
16
17
18
19

20
21 In Germany, increased mental healthcare demands are also reflected in the recently growing number
22 of specialized psychiatric outpatient clinics and other services addressing adults with autism or adults
23 seeking diagnostic clarification of potential autism. These developments certainly represent major
24 advancements. However, adults seeking autism diagnostics, post-diagnostic treatment or counselling),
25 psychotherapy and other specialized or supportive services in Germany can be confronted with waiting
26 times up to two-three years^{14 21 22}. Autistic adults seeking psychotherapy reported that the main reason
27 for not receiving any or insufficient treatment was an expressed lack of professional expertise about
28 autism^{14 21}. Accordingly, therapists also reported barriers due to limited training, experience and low
29 confidence with respect to treating autism despite high motivation for comprehensive care²³. In fact,
30 diagnosis and treatment of autism indeed require qualified training, can be time- and cost-intensive and
31 often lack validated therapeutical manuals or instruments for use in autistic adults²⁰.
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 Thus, lack of professional knowledge or training can be considered a major barrier; yet, multiple other
47 difficulties or barriers have been suggested, which prevent effective and efficient mental healthcare for
48 adults with autism especially for those who struggle with comorbid mental or medical health problems¹⁷.
49 Barriers have been discussed at different levels, nationally²⁴ as well as internationally²⁵⁻³¹, at (i) an
50 *individual* level due to autism-related social-communicative impairments, perceptual peculiarities or
51 difficulties with practical skills of daily living (e.g., when making appointments), (ii) a *system-related or*
52 *structural* level (e.g., lack of services or reduced service accessibility across healthcare sectors for autistic
53
54
55
56
57
58
59
60

1
2
3
4 adults), and (iii) *professional* level (e.g., lack of training/ knowledge or stigma about adult autism). Yet,
5
6 factors that facilitate healthcare for adults with autism have also been suggested (e.g., appointment
7
8 coordination via e-mail, special stimulus-reduced waiting areas, autism-specific training for healthcare
9
10 providers, shared decision making, cooperation with relatives/ partners, case managers or coordination
11
12 through general practitioners, transition management, medical care centers or financial facilitations for
13
14 healthcare services)^{17 26}.

15
16
17
18 Amongst these facilitatory factors, transition management from a familiar and guided pediatric care
19
20 system to a complex and self-managed care system for adults seems particularly important^{12 32-34} ,
21
22 considering autism to be a neurodevelopmental condition with limited flexibility and resistance to change.
23
24 Assistance with transition could not only foster self-management of young autistic adults but also reduce
25
26 potential burden of care for relatives. In fact, relatives typically compensate for the lack of assistance or
27
28 services, thereby often facing extensive personal and financial burden^{35 36} and reduced health-related
29
30 quality of life themselves^{37 38}. The amount of evidence on the consequences of an insufficient healthcare
31
32 system for relatives of autistic adults—not only children—is limited. In addition, support from relatives
33
34 might not always be available considering the increased age of autistic adults, difficult familial relations
35
36 or high family concordance rates³⁹. With increasing prevalence rates of autism⁴⁰, however, a rising
37
38 number of autistic individuals will be transitioning to adult healthcare and needing assistance to access
39
40 the appropriate healthcare services. Interventions at several levels and assistance with respect to
41
42 navigation within the healthcare system will also be required to reduce caregiver burden in autism⁴¹.

43
44
45
46
47
48 In sum, autistic adults but also their relatives and healthcare providers face barriers and are in need of
49
50 extended services. Recognizing autism as a lifelong condition will be a fundamental first step. Yet, in
51
52 order to increase access, capacity and quality of care for autistic adults, it will be necessary to (i)
53
54 systematically understand the factors that lead to poorer health status and ineffective healthcare by
55
56 including the perspectives of all people involved in healthcare access for autistic adults²⁵, (ii)
57
58 operationalize individual levels of support, define necessary services and their indications, (iii) make
59
60

1
2
3
4 these information easily accessible to all relevant stakeholders, and (iv), finally, implement evidence-
5 based healthcare programs for autistic adults. Previous evidence was helpful in identifying barriers and
6
7 pointing to future directions. Many suggestions, however, have yet to find their way into healthcare
8
9 politics and services, much less being implemented in routine practice. In addition, recommendations
10
11 often lacked specifics or operationalizations with respect to the selection of services or interventions
12
13 depending on the individual level of disability and required support (compare to the recent Lancet
14
15 commission on the future of care in autism: “Crucial factors include understanding what works for whom
16
17 and when, and what are some of the predictable needs and variations that need to be considered to support
18
19 autistic individuals”⁴²).
20
21
22
23
24

25 Thus, with the current study we seek to, first, systematically analyze current barriers, facilitators and
26
27 unmet needs—including their economic and personal consequences—in mental healthcare of adults with
28
29 autism in Germany at three relevant levels (individual, structural and professional) and from three relevant
30
31 perspectives (autistic adults, relatives and healthcare providers). While the focus of the study is on mental
32
33 healthcare (i.e., particularly, diagnosis, therapy and supportive services), the study will also examine all
34
35 health-related services relevant for autistic adults given the afore-mentioned complexity of the condition.
36
37 Second, we seek to use these data to develop specific recommendations for a need-oriented, future model
38
39 of mental healthcare and supporting services for autistic adults, which will consider the heterogeneity
40
41 within the autism spectrum, different service needs and individual indications for services. Third, this
42
43 model will be evaluated by the three stakeholder groups and analyzed with respect to implementation in
44
45 healthcare routines and cost-effectiveness. During all phases, the study will strengthen a participatory
46
47 research approach by engaging autism-trained clinicians and autistic adults in the scientific process and
48
49 by collaborating with autism-, parental- and service-related associations. The long-term aim of the study
50
51 is to contribute to more effective mental healthcare for autistic adults by providing specific
52
53 recommendations for clinical practice and healthcare policies, also improving mental health outcomes for
54
55 autistic adults and those who support them.
56
57
58
59
60

METHODS AND ANALYSIS

This study protocol was written in adherence with the SPIRIT (Standardized Protocol Items for Randomized Trials) checklist for study protocols for items applicable to the present protocol of a non-interventional, observational study.

Study population

Three stakeholder perspectives will be assessed. We will recruit (i) autistic adults with varying degrees of needed support, (ii) close relatives (first or second degree) or partners of early- and late-diagnosed autistic adults, and (iii) healthcare service providers throughout Germany. For qualitative data collection (i.e., focus groups), we will primarily recruit providers of mental healthcare services with experience in treating patients or clients with autism in order to gain central information about the current state of mental healthcare, including barriers and needs, for autistic adults in Germany and to support coherent discussions. Primary care practitioners and pediatricians will also be recruited due to their particular role in transition and coordination of care. Given the often complex health status and broad service needs of autistic adults as well as supposed barriers throughout the care system (e.g., due to lack of knowledge about autism), the large-scale online surveys will also include data from healthcare providers with various professional backgrounds and levels of experience with autism (from working in autism-specific services to more general services or no expertise in autism) in order to gather a more comprehensive and representative picture on barriers and needs with respect to treating autistic adults and to examine whether qualitatively identified barriers and needs also apply to different healthcare settings. Inclusion of different professional backgrounds and levels of experience with autism along with other relevant criteria (e.g., geographic distribution, urban or countryside, etc.) will be ensured by pre-defined recruitment strategies

1
2
3
4 and collection of corresponding sociodemographic data via questionnaire in the recruitment and data
5
6 collection process.
7

8
9 Participants with autism must be adults (18+ yrs.) and must have a secured diagnosis of autism
10
11 without intellectual disability ($IQ > 70$), sufficient ability to provide informed consent and sufficient
12
13 language skills to answer the questions. Participants with intellectual disability ($IQ < 70$), insufficient
14
15 German skills and ability to give informed consent will be excluded. Participants will be recruited
16
17 throughout Germany using purposive, quota and snowball sampling via the study's collaborating network
18
19 of cooperating partners, publicly available contacts from autism-related associations (incl. self-care and
20
21 caregiver groups), healthcare associations (medical chambers, therapist associations, etc.), local and
22
23 countrywide outpatient clinics as well as social media. Participants will be informed in detail about the
24
25 study and data protection in accordance with the General Data Protection Regulation, and informed
26
27 consent will be obtained prior to participation. No expense allowance will be paid (with the exception of
28
29 possible travel expenses for participation in interviews/focus groups).
30
31
32
33
34
35

36 **Study design and data collection**

37
38 The study will evolve over a period of three years (Oct. 2020 - Sept.2023). A three-phase design will be
39
40 implemented (Fig. 1).
41
42
43
44

45 ----- *please insert Figure 1 about here* -----
46
47
48
49

50 Phase 1: Healthcare and needs analysis

51
52 First, a literature search on national and international evidence will be conducted in PubMed to identify
53
54 previously published barriers, facilitators and needs related to healthcare and mental healthcare of adults
55
56 with autism. Results will be used to develop guideline questions for qualitative data collection. Three
57
58 interview guides will be developed, tailored to each stakeholder group. Participants' experiences with
59
60

1
2
3
4 healthcare or with provision of services/ treatment of autistic adults will be assessed. Barriers, facilitators,
5
6 and needs in healthcare of autistic adults, especially with focus on mental healthcare (i.e., diagnostics,
7
8 therapy and assisting services), at individual, professional, and structural levels and recommendations for
9
10 improving mental healthcare for autistic adults will be discussed. Guideline questions will be
11
12 administered by trained researchers in semi-structured one-on-one interviews with autistic adults (n=15)
13
14 and structured focus groups with relatives/ partners of autistic adults (n=15) as well as healthcare
15
16 providers (n=15). All interviews and focus groups will be audio-recorded. An external, specifically
17
18 transcription-qualified and bound to secrecy person will transcribe recordings verbatim. Because of the
19
20 dynamics of the Covid-19 pandemic, interviews and focus-groups will be conducted online enabled by
21
22 an online video communication provider. To meet individual difficulties in communication and
23
24 flexibility, participants with autism will also be given the chance to answer interview questions in a
25
26 written format, via chat or phone. All qualitative data will be pseudonymized, i.e., personal identifying
27
28 information (e.g., names) will be removed. Only pseudonymized data will be further analyzed. All data
29
30 will be stored on secured servers of the University Medical Center Hamburg-Eppendorf.
31
32
33
34
35

36
37 Second, open-ended and close-ended items (e.g., implementing a five-point Likert scale) on
38
39 barriers and needs in mental healthcare of autistic adults will be generated through consented discussion
40
41 in the research team based on qualitative results, i.e., themes, that emerged from interviews/ focus groups.
42
43 The mixed-methods approach aims to obtain a complete set of information to develop specific
44
45 recommendations for a future healthcare model for autistic adults. These items will be similarly assessed
46
47 across stakeholder groups. In addition, items specific to each group of participants will be included such
48
49 as items related to service provision in professionals (e.g., waiting times), related to informal care in
50
51 relatives, and to service utilization and comorbidities in autistic adults. Thus, separate online surveys will
52
53 be developed for each stakeholder group (autistic adults; relatives of autistic adults; healthcare providers)
54
55 that will be used to collect quantitative data in larger samples and provide an overview of the healthcare
56
57 situation for adults with autism in Germany from multiple perspectives.
58
59
60

1
2
3
4 Online surveys, i.e., barrier- and needs-related items, will be explored with respect to
5
6 psychometric properties, such as content and construct validity, discriminability and internal consistency,
7
8 for example, via correlational or exploratory factor analyses. We will also examine floor and ceiling
9
10 effects using descriptive analyses. As proxy for acceptability, we will examine patterns of missing data
11
12 or low response rates. In addition, standardized, psychometric questionnaires and patient-reported
13
14 outcomes will be employed in participants with autism and relatives. They will be asked to complete
15
16 questionnaires related to health-related quality of life (e.g., EQ-5D-5L)⁴³, disability/ functioning (e.g.,
17
18 WHODAS 2.0)⁴⁴ and a German version of the “barriers to healthcare” questionnaire²⁹. Relatives will
19
20 additionally be asked to rate their burden of care (e.g., iVICQ/CarerQoL)⁴⁵. These represent previously
21
22 validated instruments with good overall validity and reliability^{29 43-45}. Moreover, in both groups, variables
23
24 related to disease/healthcare history, utilization of medical and non-medical services, and productivity
25
26 losses will be collected (e.g., days spent on sick leave, hospital days, physician contacts, or informal care)
27
28 through modified versions of the FIMA and FIMPsy questionnaires^{46 47}.

29
30
31
32
33
34 Person-identifying information will not be requested. Online surveys will be delivered
35
36 countrywide by an online survey software in German based at protected servers. Separate survey versions
37
38 will be provided to autistic adults (n=250), relatives (n=125) and healthcare providers (n=125).
39
40 Participation will take place in a completely anonymized manner. Participants will be automatically
41
42 assigned randomly generated IDs. Personal information entered in free text fields will be removed or
43
44 anonymized. Data collection will be continuously monitored and managed by members of research team.
45
46
47
48
49

50 Phase 2: Development of recommendations for a future healthcare model for autistic adults

51
52 A literature search on possibly existing healthcare recommendations or implementation models for adults
53
54 with autism and related conditions will be conducted in PubMed and Google and –together with the results
55
56 from the mixed-methods data in Phase 1—fed into the development of an extended, need-oriented mental
57
58 healthcare model for autistic adults. This model will include recommendations for actions/interventions
59
60

1
2
3
4 at different levels (individual, structural and professional) and will be addressed to the stakeholder groups
5 (autistic adults; relatives of autistic adults; healthcare providers and policy makers/ politics; Figure 2).
6
7 Given the heterogeneity of symptom severity, functional impairments, rates of comorbidity and needed
8
9 support within the autism spectrum, a multi-professional stepped or collaborative care approach as
10
11 proposed for, e.g., psychosis or depression⁴⁸, might represent a possible framework for an alternative care
12
13 model as opposed to current standard care for autistic adults (as also suggested by⁴²). Stepped mental
14
15 healthcare for autism may range from low-level, evidence-based services (e.g., educational programs or
16
17 information/ consulting about autism and available treatment options, e-mental health) over mid-level
18
19 (e.g., improved diagnostics, autism-informed psychotherapy, occupational therapy or sociotherapy) to
20
21 high-level services, which are often unavailable to adults with autism in Germany (e.g., case managers,
22
23 integrated care, medical healthcare centers, inpatient care). Recommendations for possible individual
24
25 steps, services offered within each step and indications for services will be specified. Besides
26
27 recommendations for autistic adults, the future healthcare model will also provide recommendations for
28
29 relatives of autistic adults, healthcare providers and policy makers (Fig. 2). More specifically, relatives
30
31 or partners who support an autistic adult are often in need of support themselves. Thus, the model will
32
33 also include recommendations for relatives. Conversely, for healthcare providers, recommendations could
34
35 include suggestions to advance knowledge about specific needs of autistic adults and promote awareness
36
37 for these needs in different mental healthcare sections. For policy makers, recommendations will focus
38
39 on extended services to reduce structural barriers. These will be underlined by the health-economic data
40
41 collected within Phase 1 and 3.
42
43
44
45
46
47
48
49
50
51

52 ----- *please insert Figure 2 about here* -----
53
54
55

56
57 Phase 3: Evaluation and implementation analysis
58
59
60

1
2
3
4 Methods will be analogous to Phase 1 (mixed-methods, qualitative interviews/ focus groups and
5 quantitative online surveys with autistic adults, relatives of autistic adults and healthcare providers) with
6 emphasis on evaluation and implementation of the developed recommendations for a future healthcare
7 model. Based on the "Consolidated Framework for Implementation Research," an implementation of the
8 model will be explored to improve the feasibility of a potential implementation⁴⁹. The developed model
9 and its components will be evaluated by all stakeholder groups in a structured evaluation process based
10 on different dimensions such as acceptability, appropriateness, cost, feasibility and sustainability⁵⁰. In
11 Phase 3, participants from Phase 1 will be re-recruited or, if this is not possible, comparable
12 representatives will be invited. In addition, we will invite participants from other backgrounds such as
13 healthcare politics/ policies. Furthermore, participants will be, for example, asked to rate to what extent
14 (i) barriers and needs identified during Phase 1 will be addressed by the model, (ii) whether suggested
15 services are already implemented in standard German healthcare, (iii) which services might be easier or
16 more feasible to be implemented and (iv) give feedback about service requirements (e.g., indications,
17 training, time/ financial resources, personnel). The mixed-methods design (incl. open-ended questions
18 during online surveys) will allow direct feedback and potential indications for modifications. In addition,
19 standardized implementation-related questionnaires will be employed^{e.g., 51}. As the model's actual
20 implementation is not part of the study, we would like to use this phase to gather enough information,
21 including positive and critical aspects, for a potential implementation. Finally, based on the results of
22 Phase 3 the developed recommendations and model for improving healthcare for autistic adults will be
23 reviewed and, if necessary, revised.

51 Sample sizes

52
53 Based on power calculation, a minimum of n=500 participants will be aimed at for each quantitative
54 online survey. This sample size represents the minimum number of participants needed for group
55 comparisons with at least medium effect sizes (d=0.50) at a power of 80% and an alpha error of 5%.

1
2
3
4 Previously published related online surveys with autistic participants or caregivers have reported dropout
5 rates of 15% to 35% due to reasons such as incomplete or duplicate responses, failure to consent or to
6 meet inclusion criteria^{52,53}. Thus, here to compensate for dropouts, participants will be over-recruited (i.e.,
7 a dropout rate of 15% would correspond to 75 additional participants). The motivation to participate in
8 scientific studies can be considered high in the autism community, particularly regarding participation in
9 online surveys and research with impact to their everyday life. Yet, if recruitment targets are not met, the
10 following steps will be taken to achieve planned sample sizes: extension of the data collection time
11 window, increased networking as well as enhanced promotion of our research via associations, social
12 media and community outreach.
13
14
15
16
17
18
19
20
21
22
23
24

25 Qualitative data will not be used for direct hypotheses testing so that sample size does not need to
26 be based on power analyses. Here sample size (a total of N=90) was chosen based on previously
27 published recommendations⁵⁴.
28
29
30
31
32
33

34 **Data analyses**

35
36 *Qualitative data* from Phase 1 and 3 will be analyzed according to the thematic analysis approach⁵⁵ using
37 the software MAXQDA. Deductive or theoretical categories based on previously published evidence
38 relevant to each phase will drive the analyses. Because the study will focus on subjective experiences/
39 perspectives, data analyses will be complemented by an inductive approach. Data analyses will be
40 conducted by two trained researchers. Emerging themes, subthemes and codes related to barriers and
41 needs in mental healthcare (Phase 1) and evaluation/ implementation of derived recommendations for
42 extended care (Phase 3) will be discussed by the two researchers and agreed upon by the research team.
43
44
45
46
47
48
49
50
51
52
53 A third researcher will be consulted upon disagreement.
54

55 *Quantitative data* from online surveys in Phase 1 and 3 will be exported to and analyzed using the
56 statistical software SPSS and R. Before analyses, exported survey data will be manually checked by
57 members of the research team. We will run descriptive statistical analyses and report
58
59
60

1
2
3
4 frequencies/percentages, means/medians and standard deviations/interquartile ranges separate for each
5 stakeholder group on, if applicable, (i) sociodemographic data (e.g., age, gender, education, employment
6 status, profession), (ii) clinical data (e.g., diagnosis, comorbidities, service utilization), (iii) objective
7 healthcare indicators (e.g., waiting times for or distances of services), (iv) subjective ratings on barriers
8 and needs in mental healthcare (Phase 1) or evaluative ratings on implementation of the developed care
9 model (Phase 3)^{49 50}, and (v) on implemented standardized questionnaires related to barriers to
10 healthcare²⁹, health-related quality of life⁴³, disability and functioning⁴⁴, burden of care⁴⁵ and
11 implementation^{e.g. 51}. Primary outcome will be service utilization in the last six months as assessed in the
12 online surveys and groups of autistic adults and relatives. In order to determine predictors of healthcare
13 utilization of autistic adults in Germany and, thus, also inform the development of an extended care model
14 in Phase 2 (e.g., indications for services^{cf. 42}), multiple regression analyses will be conducted. The
15 following variables will be tested as potential predictors, i.e., enabling or disabling healthcare utilization:
16 sociodemographic variables (e.g., gender, age, education), autism diagnosis, symptom severity/ level of
17 required support according to DSM-5³, comorbidity, and experienced barriers to healthcare as
18 operationalized by the score on the “barriers to healthcare” questionnaire²⁹ as well as by ratings from our
19 own online survey. With respect to the latter, a factor analysis will be performed in order to identify
20 underlying dimensions. Scores of factors with the highest variance will then be used as predictors for
21 regression analyses. In secondary, more exploratory, analyses, we aim to test for mean differences
22 between stakeholder groups on subjective ratings of barriers and needs in mental healthcare (Phase 1) and
23 evaluation/ implementation of the developed need-oriented model (Phase 3), using stakeholder group as
24 independent variable and ratings as dependent variable employing parametric or non-parametric statistical
25 tests depending on scale level and data distribution. Quantitative data will be tested statistically based on
26 95% confidence intervals.

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57 *Health-economic analyses* in Phase 1 and 3 will be informed by a previously conducted systematic
58 review of the literature on cost-of-illness and cost-effectiveness studies in autism. The systematic review
59
60

1
2
3
4 will be carried out in agreement with the PRISMA guidelines. Standard databases such as Medline/
5 PubMed and PsycInfo as well as reference lists will be searched for international studies in English or
6
7 German. The search term will focus on “costs of illness”, “health expenditures”, “cost effectiveness” or
8
9 “cost analysis”, “burden of illness”, “economic burden” and “autism spectrum disorders”, combined with
10
11 Boolean operators. In Phase 1, in addition to service utilization, productivity losses in the last six months
12
13 as well as out-of-pocket payments will be directly assessed in autistic adults. In addition, relatives will
14
15 also be asked about aspects that might be related to their autistic relative, like informal care provision or
16
17 reduced working time. To estimate direct costs, service utilization will be evaluated in monetary terms
18
19 using standardized unit costs^{56,57}. Indirect costs due to productivity losses (e.g., due to incapacity to work)
20
21 will be estimated with the human capital approach. The estimated costs for autistic adults will then be
22
23 compared to the general German population, and excess costs will be calculated⁵⁸. Under the assumption
24
25 that differences in sociodemographic covariates or comorbidities across groups are adjusted, the excess
26
27 cost approach enables the analysis of all costs attributable to autism. Based on the skewed distribution of
28
29 cost data, cost differences will be calculated using generalized linear models with gamma distribution and
30
31 log-link function. Our findings will also be compared to other evidence on cost-of-illness in autism and
32
33 other mental health conditions such as depression as common mental disorder, schizophrenia as disorder
34
35 with similar prevalence, or ADHD as other developmental disorder. In Phase 3, health-economic analyses
36
37 will focus on the evaluation of the potential costs and effects of the developed future healthcare model
38
39 using health-economic modelling. The cost-effectiveness analysis will assess the incremental cost-
40
41 effectiveness ratio of the developed healthcare model compared to the status quo. This is calculated as
42
43 the ratio of the difference in costs (between healthcare intervention and status quo) to the difference in
44
45 health effects of both respective groups. The costs are to be determined from a societal perspective, i.e.,
46
47 in addition to purely medical costs, non-medical costs and monetarily assessed productivity losses will
48
49 also be taken into account. As a measure of the health effects, i.e., health-related quality of life, quality-
50
51 adjusted life years (QALYs) will be estimated based on the findings from the EQ-5D-5L⁴³.
52
53
54
55
56
57
58
59
60

Patient and public involvement

The stakeholders' perspectives are systematically included given the mixed-methods design. Research will be undertaken in close collaboration with federal and local patient, parental and healthcare or autism-related organizations, from which we obtained collaboration agreements prior to submission to the funding agency as well as during the initial course of the study. Representatives of these organizations will be continuously informed over the course of the study via regular meetings and asked to provide feedback during each study phase. They will also be invited to participate in focus groups and qualitative interviews and asked to support further recruitment of study participants. Cooperation partners and all other study participants from focus groups and interviews will be offered to receive quarterly newsletters about the course and interim findings of the study. For all other participants (e.g., who anonymously took part in the online surveys), information will be made publicly available on a project website. Participants will be given the possibility to express feedback or concerns via the project's email-address or direct contact to one of our (peer) researchers.

ETHICS AND DISSEMINATION

Ethics approval and consent to participate

The study will be carried out in accordance with the WMA Declaration of Helsinki and has been approved by the Local Psychological Ethics Commission of the Center for Psychosocial Medicine of the University Medical Center Hamburg-Eppendorf (ref.# LPEK-0227). Study participation is voluntary and no foreseeable risks for participants result from the participation. Participants will be fully informed about the aims of the study, data collection, handling and storage. Written informed consent will be obtained before participation. Preserving principles of data sensitivity, data protection and confidentiality requirements will be met.

Dissemination

Findings will be disseminated via national and international scientific meetings and peer-reviewed journals in the field of autism and healthcare research. Cooperating partners and associations will be informed about the study's course and findings by quarterly newsletters and biannual meetings. Study participants from focus groups and interviews will also receive quarterly newsletters about the progression and outcomes of the study. Information, including study information, posters and presentations, will also be disseminated via the project's webpage.

DISCUSSION

This study protocol outlines several urgent challenges related to mental healthcare for autistic adults in Germany. The study will provide a systematic analysis of the current state of healthcare for adults with autism, including barriers and requirements experienced by autistic persons themselves, but also their relatives and healthcare providers. The results will be used to facilitate a real-world, data-informed and evidence-based future model of mental healthcare for autistic adults, which seeks to overcome current barriers by developing specific practice recommendations at individual, structural and professional levels aiding all stakeholder groups. The model will provide suggestions for all involved stakeholders including policy makers.

Strengths and limitations

One strength of this study is that it aims to define individual characteristics that might be useful to assess a person's need of support and provide specific treatment suggestions and indications for mental healthcare and other related services that are relevant for autistic adults ("understanding what works for whom and when"⁴²). Another strength is that this study will evaluate the developed recommendations and

1
2
3
4 model conceptions for future care with respect to implementation chances, acceptability, feasibility,
5 sustainability, cost-effectiveness and other dimensions and prepare for a future implementation. As such,
6
7 the current study goes beyond previously published analyses of healthcare and published suggestions for
8
9 improvement of care for autistic individuals, adults in particular.
10
11
12

13
14 For a long time, research or healthcare politics have overlooked, neglected or ignored autistic
15 individuals and their families in information and decision-making processes^{52 59}. Here, participatory
16 research will be realized in a threefold fashion. First, results will be obtained by directly asking those who
17 are affected (autistic adults, relatives, and healthcare providers) about real-world experiences and their
18 attitude towards the developed research. Second, researchers serving mental healthcare of adults with
19 autism, and researchers with autism will conduct the study. Third, the research will be undertaken in close
20 collaboration with patient, parental and healthcare organizations, which will be continuously informed
21 over the course of the study and asked to provide feedback during each study phase.
22
23
24
25
26
27
28
29
30
31

32 One limitation of the study is that the developed mental healthcare model for adults with autism
33 will not be practically applied during the course of the study. Future funding will be necessary to test
34 implementation, clinical effectiveness and sustainability of the developed recommendations and services,
35 for example, within a randomized controlled trial. This will allow for further refinement and specifics to
36 foster large-scale implementation. Yet, as the study is funded by the German Federal Joint
37 Committee—the highest decision-making body of the joint self-government of practitioners,
38 hospitals and health insurance funds in Germany—this study will likely have a direct and
39 immediate impact on healthcare policies and contribute to improving outcomes in people and families
40 with autism and reducing individual, familial and socioeconomic burdens associated with a lack of
41 services for adults with autism.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

1
2
3
4 We would like to acknowledge the support of our cooperation partners and supporters: the Autism
5
6 Research Cooperation (afk), autSocial e.V., the Federation of Autism in Germany (Autismus Deutschland
7
8 e.V.), the parent association Autismus Hamburg e.V., the Autism Institute of Hamburg, the Autism
9
10 Institute of Lübeck, the Autism Strategy for Bavaria (Prof. M. Witzmann), Practice for Psychotherapy
11
12 Aida Knabe and others.
13
14
15
16
17

18 **Author contributions**

19
20 HS is the main PI for the study; DS, AK, KV, ND and JP are co-PIs. They all conceptualized and designed
21
22 the study. SD, PG, HK, PR and FE are research staff. SD is also a graduate student. ND and JP mainly
23
24 drafted this manuscript. All authors participated, reviewed and edited the manuscript; all authors approved
25
26 the final version of the manuscript.
27
28
29
30
31

32 **Funding**

33
34 This work was supported by the Innovation Fund of the German Federal Joint Committee (Gemeinsamer
35
36 Bundesausschuss, G-BA, study "*BarrierefreiASS*"/ grant number: 01VSF19011 awarded to HS (PI)).
37
38 The funding body had no role in the design of the study or in writing the manuscript, nor will they have
39
40 a role in data collection, analyses or interpretation of data.
41
42
43
44
45

46 **Competing interests**

47
48 DS received honoraria for lectures from or has been an advisor to Janssen GmbH, ROVI, Lundbeck
49
50 GmbH, Otsuka Pharma GmbH and Takeda. The remaining authors do not declare other competing
51
52 interests.
53
54
55
56
57
58

59 **REFERENCES**

- 1
2
3
4 1. Baio J, Wiggins L, Christensen DL, et al. Prevalence of Autism Spectrum Disorder Among Children
5 Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States,
6
7
8
9 2014. *MMWR Surveill Summ* 2018;67(6):1-23. doi: 10.15585/mmwr.ss6706a1 [published Online
10
11
12 First: 2018/04/28]
- 13
14 2. Lundstrom S, Reichenberg A, Anckarsater H, et al. Autism phenotype versus registered diagnosis in
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 2. Lundstrom S, Reichenberg A, Anckarsater H, et al. Autism phenotype versus registered diagnosis in
Swedish children: prevalence trends over 10 years in general population samples. *BMJ*
2015;350:h1961. doi: 10.1136/bmj.h1961 [published Online First: 2015/04/30]
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed.
Washington, DC2013.
4. Hirvikoski T, Mittendorfer-Rutz E, Boman M, et al. Premature mortality in autism spectrum disorder.
Br J Psychiatry 2016;208(3):232-8. doi: 10.1192/bjp.bp.114.160192 [published Online First:
2015/11/07]
5. Croen LA, Zerbo O, Qian Y, et al. The health status of adults on the autism spectrum. *Autism*
2015;19(7):814-23. doi: 10.1177/1362361315577517 [published Online First: 2015/04/26]
6. Kohane IS, McMurry A, Weber G, et al. The co-morbidity burden of children and young adults with
autism spectrum disorders. *PLoS One* 2012;7(4):e33224. doi: 10.1371/journal.pone.0033224
[published Online First: 2012/04/19]
7. Nicolaidis C, Kripke CC, Raymaker D. Primary care for adults on the autism spectrum. *Med Clin North*
Am 2014;98(5):1169-91. doi: 10.1016/j.mcna.2014.06.011 [published Online First: 2014/08/20]
8. Vohra R, Madhavan S, Sambamoorthi U. Comorbidity prevalence, healthcare utilization, and
expenditures of Medicaid enrolled adults with autism spectrum disorders. *Autism* 2017;21(8):995-
1009. doi: 10.1177/1362361316665222 [published Online First: 2016/11/23]
9. Mason D, Mackintosh J, McConachie H, et al. Quality of life for older autistic people: The impact of
mental health difficulties. *Res Autism Spect Dis* 2019;63:13-22. doi: 10.1016/j.rasd.2019.02.007

10. Mason D, McConachie H, Garland D, et al. Predictors of quality of life for autistic adults. *Autism Res* 2018;11(8):1138-47. doi: 10.1002/aur.1965
11. Vohra R, Madhavan S, Sambamoorthi U. Emergency Department Use Among Adults with Autism Spectrum Disorders (ASD). *J Autism Dev Disord* 2016;46(4):1441-54. doi: 10.1007/s10803-015-2692-2 [published Online First: 2016/01/15]
12. Ames JL, Massolo ML, Davignon MN, Qian Y, Croen LA. Healthcare service utilization and cost among transition-age youth with autism spectrum disorder and other special healthcare needs. *Autism*. 2021 Apr;25(3):705-718. doi: 10.1177/1362361320931268.
13. Schott W, Nonnemacher S, Shea L. Service Use and Unmet Needs Among Adults with Autism Awaiting Home- and Community-Based Medicaid Services. *J Autism Dev Disord*. 2021 Apr;51(4):1188-1200. doi: 10.1007/s10803-020-04593-2.
14. Lipinski S, Blanke ES, Suenkel U, et al. Outpatient Psychotherapy for Adults with High-Functioning Autism Spectrum Condition: Utilization, Treatment Satisfaction, and Preferred Modifications. *Journal of Autism and Developmental Disorders* 2019;49(3):1154-68. doi: 10.1007/s10803-018-3797-1
15. Croteau C, Mottron L, Dorais M, Tarride JE, Perreault S. Use, costs, and predictors of psychiatric healthcare services following an autism spectrum diagnosis: Population-based cohort study. *Autism*. 2019 Nov;23(8):2020-2030. doi: 10.1177/1362361319840229.
16. Platos M, Pisula E. Service use, unmet needs, and barriers to services among adolescents and young adults with autism spectrum disorder in Poland. *Bmc Health Serv Res* 2019;19(1) doi: 10.1186/s12913-019-4432-3
17. Maddox BB, Crabbe S, Beidas RS, et al. "I wouldn't know where to start": Perspectives from clinicians, agency leaders, and autistic adults on improving community mental health services for autistic adults. *Autism* 2020;24(4):919-30. doi: 10.1177/1362361319882227 [published Online First: 2019/11/02]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18. Vogan V, Lake JK, Tint A, et al. Tracking health care service use and the experiences of adults with autism spectrum disorder without intellectual disability: A longitudinal study of service rates, barriers and satisfaction. *Disabil Health J* 2017;10(2):264-70. doi: 10.1016/j.dhjo.2016.11.002 [published Online First: 2016/12/03]
 19. Hofer J, Hoffmann F, Dorks M, et al. Health Services Use and Costs in Individuals with Autism Spectrum Disorder in Germany: Results from a Survey in ASD Outpatient Clinics. *J Autism Dev Disord* 2021 doi: 10.1007/s10803-021-04955-4 [published Online First: 2021/03/18]
 20. Kamp-Becker I, Poustka L, Bachmann C, et al. Study protocol of the ASD-Net, the German research consortium for the study of Autism Spectrum Disorder across the lifespan: from a better etiological understanding, through valid diagnosis, to more effective health care. *BMC Psychiatry* 2017;17(1):206. doi: 10.1186/s12888-017-1362-7 [published Online First: 2017/06/05]
 21. Lipinski S, Boegl K, Blanke ES, Suenkel U, Dziobek I. A blind spot in mental healthcare? Psychotherapists lack education and expertise for the support of adults on the autism spectrum. *Autism*. 2021 Nov 26:13623613211057973. doi: 10.1177/13623613211057973.
 22. Gawronski A, Kuzmanovic B, Georgescu A, et al. [Expectations concerning psychotherapy of high-functioning adults with autism spectrum disorders]. *Fortschritte der Neurologie-Psychiatrie* 2011;79(11):647-54. doi: 10.1055/s-0031-1281734 [published Online First: 2011/10/19]
 23. Brookman-Frazee L, Drahota A, Stadnick N, et al. Therapist Perspectives on Community Mental Health Services for Children with Autism Spectrum Disorders. *Adm Policy Ment Hlth* 2012;39(5):365-73. doi: 10.1007/s10488-011-0355-y
 24. Dern S, Sappok T. Barriers to healthcare for people on the autism spectrum. *Adv Autism* 2016;2(1):2-11. doi: 10.1108/Aia-10-2015-0020
 25. Calleja S, Islam FMA, Kingsley J, et al. Healthcare access for autistic adults A systematic review. *Medicine* 2020;99(29) doi: 10.1097/Md.0000000000020899

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
26. Mason D, Ingham B, Urbanowicz A, et al. A Systematic Review of What Barriers and Facilitators Prevent and Enable Physical Healthcare Services Access for Autistic Adults. *J Autism Dev Disord* 2019;49(8):3387-400. doi: 10.1007/s10803-019-04049-2 [published Online First: 2019/05/28]
 27. Fenikile TS, Ellerbeck K, Filippi MK, et al. Barriers to autism screening in family medicine practice: a qualitative study. *Prim Health Care Res* 2015;16(4):356-66. doi: 10.1017/S1463423614000449
 28. Malik-Soni N, Shaker A, Luck H, et al. Tackling healthcare access barriers for individuals with autism from diagnosis to adulthood. *Pediatr Res* 2021 doi: 10.1038/s41390-021-01465-y
 29. Raymaker DM, McDonald KE, Ashkenazy E, et al. Barriers to healthcare: Instrument development and comparison between autistic adults and adults with and without other disabilities. *Autism* 2017;21(8):972-84. doi: 10.1177/1362361316661261
 30. Nicolaidis C, Raymaker D, McDonald K, et al. Comparison of Healthcare Experiences in Autistic and Non-Autistic Adults: A Cross-Sectional Online Survey Facilitated by an Academic-Community Partnership. *J Gen Intern Med* 2013;28(6):761-69. doi: 10.1007/s11606-012-2262-7
 31. Nicolaidis C, Raymaker DM, Ashkenazy E, et al. "Respect the way I need to communicate with you": Healthcare experiences of adults on the autism spectrum. *Autism* 2015;19(7):824-31. doi: 10.1177/1362361315576221
 32. Freitag CM, Poustka L, Kamp-Becker I, et al. Transition in autism spectrum disorders. *Z Kinder Jug- Psych* 2020;48(6):440-42. doi: 10.1024/1422-4917/a000715
 33. King C, Merrick H, Le Couteur A. How should we support young people with ASD and mental health problems as they navigate the transition to adult life including access to adult healthcare services. *Epidemiol Psych Sci* 2020;29 doi: 10.1017/S2045796019000830
 34. Enner S, Ahmad S, Morse AM, et al. Autism: considerations for transitions of care into adulthood. *Curr Opin Pediatr* 2020;32(3):446-52. doi: 10.1097/Mop.0000000000000882
 35. Cadman T, Eklund H, Howley D, et al. Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United

- 1
2
3
4 Kingdom. *J Am Acad Child Adolesc Psychiatry* 2012;51(9):879-88. doi: 10.1016/j.jaac.2012.06.017
5
6 [published Online First: 2012/08/25]
7
8
9 36. Rogge N, Janssen J. The Economic Costs of Autism Spectrum Disorder: A Literature Review. *Journal*
10
11 *of Autism and Developmental Disorders* 2019;49(7):2873-900. doi: 10.1007/s10803-019-04014-z
12
13 37. Boehm TL, Carter EW, Taylor JL. Family Quality of Life During the Transition to Adulthood for
14
15 Individuals With Intellectual Disability and/or Autism Spectrum Disorders. *Am J Intellect Dev*
16
17 *Disabil* 2015;120(5):395-411. doi: 10.1352/1944-7558-120.5.395 [published Online First:
18
19 2015/09/01]
20
21
22 38. Johnson N, Frenn M, Feetham S, et al. Autism spectrum disorder: parenting stress, family functioning
23
24 and health-related quality of life. *Fam Syst Health* 2011;29(3):232-52. doi: 10.1037/a0025341
25
26 [published Online First: 2011/09/21]
27
28
29 39. Tick B, Bolton P, Happe F, et al. Heritability of autism spectrum disorders: a meta-analysis of twin
30
31 studies. *J Child Psychol Psychiatry* 2016;57(5):585-95. doi: 10.1111/jcpp.12499 [published Online
32
33 First: 2015/12/29]
34
35
36 40. Matson JL, Kozlowski AM. The increasing prevalence of autism spectrum disorders. *Res Autism Spect*
37
38 *Dis* 2011;5(1):418-25. doi: 10.1016/j.rasd.2010.06.004
39
40
41 41. Iadarola S, Perez-Ramos J, Smith T, et al. Understanding stress in parents of children with autism
42
43 spectrum disorder: a focus on under-represented families. *Int J Dev Disabil* 2019;65(1):20-30. doi:
44
45 10.1080/20473869.2017.1347228
46
47
48 42. Lord C, Charman T, Havdahl A, et al. The Lancet Commission on the future of care and clinical
49
50 research in autism. *The Lancet* 2022;399(10321):271-334. doi: 10.1016/S0140-6736(21)01541-5
51
52
53 43. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level
54
55 version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20(10):1727-36. doi: 10.1007/s11136-011-9903-
56
57 x [published Online First: 2011/04/12]
58
59
60

- 1
2
3
4 44. Ustun TB, Kostanjsek N, Chatterji S, et al. Measuring health and disability: manual for WHO
5 Disability Assessment Schedule (WHODAS 2.0) / edited by T.B. Üstün, N. Kostanjsek, S. Chatterji,
6 J.Rehm. Geneva: World Health Organization, 2010.
7
8
9
10
11 45. Brouwer WB, van Exel NJ, van Gorp B, et al. The CarerQol instrument: a new instrument to measure
12 care-related quality of life of informal caregivers for use in economic evaluations. *Qual Life Res*
13 2006;15(6):1005-21. doi: 10.1007/s11136-005-5994-6 [published Online First: 2006/08/11]
14
15
16
17 46. Seidl H, Bowles D, Bock JO, et al. [FIMA--questionnaire for health-related resource use in an elderly
18 population: development and pilot study]. *Gesundheitswesen* 2015;77(1):46-52. doi: 10.1055/s-
19 0034-1372618 [published Online First: 2014/05/09]
20
21
22
23 47. Grupp H, König HH, Riedel-Heller S, et al. [FIMPsy - Questionnaire for the Assessment of Medical
24 and non Medical Resource Utilisation in Mental Disorders: Development and Application]. *Psychiatr*
25 *Prax* 2018;45(2):87-94. doi: 10.1055/s-0042-118033 [published Online First: 2017/01/27]
26
27
28
29
30
31 48. Watzke B, Heddaeus D, Steinmann M, et al. Effectiveness and cost-effectiveness of a guideline-based
32 stepped care model for patients with depression: study protocol of a cluster-randomized controlled
33 trial in routine care. *BMC Psychiatry* 2014;14:230. doi: 10.1186/s12888-014-0230-y [published
34 Online First: 2014/09/04]
35
36
37
38
39
40 49. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research
41 findings into practice: a consolidated framework for advancing implementation science. *Implement*
42 *Sci* 2009;4:50. doi: 10.1186/1748-5908-4-50 [published Online First: 2009/08/12]
43
44
45
46
47 50. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual
48 distinctions, measurement challenges, and research agenda. *Adm Policy Ment Health* 2011;38(2):65-
49 76. doi: 10.1007/s10488-010-0319-7 [published Online First: 2010/10/20]
50
51
52
53 51. Lindig A, Hahlweg P, Christalle E, et al. Translation and psychometric evaluation of the German
54 version of the Organisational Readiness for Implementing Change measure (ORIC): a cross-sectional
55
56
57
58
59
60

- 1
2
3
4 study. *BMJ Open* 2020;10(6):e034380. doi: 10.1136/bmjopen-2019-034380 [published Online First:
5
6 2020/06/10]
7
8
9
10 52. Pellicano E, Dinsmore A, Charman T. What should autism research focus upon? Community views
11 and priorities from the United Kingdom. *Autism* 2014;18(7):756-70. doi:
12 10.1177/1362361314529627
13
14
15
16
17 53. Weir E, Allison C, Baron-Cohen S. Autistic adults have poorer quality healthcare and worse health
18 based on self-report data. *Mol Autism*. 2022 May 26;13(1):23. doi: 10.1186/s13229-022-00501-w.
19
20
21
22 54. Guest G, Namey E, McKenna K. How Many Focus Groups Are Enough? Building an Evidence Base
23 for Nonprobability Sample Sizes. *Field Methods* 2017;29(1):3-22. doi: 10.1177/1525822x16639015
24
25
26
27 55. Braun V, Clarke V. What can "thematic analysis" offer health and wellbeing researchers? *Int J Qual*
28 *Stud Health Well-being* 2014;9:26152. doi: 10.3402/qhw.v9.26152 [published Online First:
29 2014/10/19]
30
31
32
33 56. Bock JO, Brettschneider C, Seidl H, et al. Ermittlung standardisierter Bewertungssätze aus
34 gesellschaftlicher Perspektive für die gesundheitsökonomische Evaluation. *Gesundheitswesen*
35 2015;77(01):53-61. [published Online First: 15.07.2014]
36
37
38
39
40 57. Grupp H, König H-H, Konnopka A. Kostensätze zur monetären Bewertung von
41 Versorgungsleistungen bei psychischen Erkrankungen. *Gesundheitswesen* 2017;79(01):48-57.
42 [published Online First: 24.09.2015]
43
44
45
46
47 58. Grupp H, König HH, Konnopka A. Health care utilisation and costs in the general population in
48 Germany. *Health Policy* 2016;120(2):159-69. doi: 10.1016/j.healthpol.2015.11.005 [published
49 Online First: 2016/01/23]
50
51
52
53
54 59. Pellicano E, Stears M. Bridging Autism, Science and Society: Moving Toward an Ethically Informed
55 Approach to Autism Research. *Autism Res* 2011;4(4):271-82. doi: 10.1002/aur.201
56
57
58
59
60

1
2
3
4 **FIGURE TITLES**
5

6 **Figure 1**
7

8
9 Timeline and three study phases.
10

11 **Figure 2**
12

13 Future model of mental healthcare for adults with autism: relevant stakeholders and target groups
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Phase 1: Healthcare analysis

- Literature search on healthcare of autistic adults
- Mixed-methods:
 - Interviews/ focus groups (*qualitative data*) with autistic adults, relatives & healthcare providers (n=15)
 - Large-scale online surveys (*quantitative data*) in autistic adults (n=250), relatives (n=125) & healthcare providers (n=125)
- Health economic analysis (service utilization and costs)

Phase 3: Evaluation and implementation analysis

- Mixed-methods:
 - Interviews/ focus groups with autistic adults, relatives & healthcare providers (n=15)
 - Large-scale online surveys in autistic adults (n=250), relatives (n=125) & healthcare providers (n=125)
- Health economic analysis (cost-effectiveness)
- Finalisation of best practice recommendations

2021

2022

2023

Phase 2: Model development

Development of specific recommendations for an effective future model of mental healthcare of autistic adults

- data-informed
- evidence-based
- Individualized (stepped-care)

2-061773 on August 22, 2022. Downloaded from <http://bmjopen.bmj.com/> on June 2, 2023 by guest. Protected by copyright.

Future healthcare for adults with autism

<i>Autistic adults</i>	<i>Relatives</i>	<i>Healthcare providers</i>	<i>Healthcare politics</i>
<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare for autistic adults • Estimation of individual parameters and operationalized levels of disability and needed support • Specific recommendations for services, treatment options and assistance (e.g., stepped-care) 	<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare for autistic adults and their relatives (e.g., education, counselling, treatment options, assistance) • Specific recommendations for services and assistance to support relatives themselves 	<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare of autistic adults (e.g., education about adult autism, assessment and treatment) • Specific recommendations for services, interventions and assistance • Details on individual indications for the selection of appropriate services 	<ul style="list-style-type: none"> • Specific recommendations for minimizing barriers to mental healthcare of autistic adults (e.g., additional healthcare structures/ services such as transition or case management, financial aids)

Recommendations for general services to overcome barriers at individual, professional and structural levels

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 3 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ n/a ___
Protocol version	3	Date and version identifier	___ n/a ___
Funding	4	Sources and types of financial, material, and other support	___ 20 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 20 ___
	5b	Name and contact information for the trial sponsor	___ n/a ___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ 20 ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ n/a ___

1 Introduction

2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-8
4	rationale			
5				
6		6b	Explanation for choice of comparators	n/a
7				
8	Objectives	7	Specific objectives or hypotheses	7/8
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	n/a
11				
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
17				
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8/9
20				
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	n/a
23				
24				
25				
26		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	n/a
27				
28				
29		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	n/a
30				
31				
32		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
33				
34	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	15-17
35				
36				
37				
38				
39				
40	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	(Fig1)
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_____ 14 _____
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_____ 9, 14 _____
5				
6	Methods: Assignment of interventions (for controlled trials)			
7	Allocation:			
8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_____ n/a _____
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_____ n/a _____
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_____ n/a _____
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_____ n/a _____
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_____ n/a _____
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_____ 10-13 _____
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_____ n/a _____
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___10, 11,15___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___15-17___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___15-16___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___n/a___
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___n/a___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___n/a___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___n/a___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___n/a___
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___3, 17/ 18___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___n/a___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	9, 18
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10/ 11
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	20/ 21
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	3, 18
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	n/a
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by/4.0/)" license.